Erlotinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Erlotinib comprises 646 peer-reviewed publications across 15 journals, 55 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, and Pancreatic Neoplasms. Most recent publication: Prospective evaluation of genomics-guided off-label treatment., Nature, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
    Wu YL, Lee JS, Thongprasert S, et al. · Lancet Oncol · 2013
    PubMed: PMID 23782814 · NCT02098954 · Carcinoma, Non-Small-Cell Lung
  2. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, et al. · Lancet Oncol · 2015
    PubMed: PMID 25175099 · NCT02759614
  3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R, Carcereny E, Gervais R, et al. · Lancet Oncol · 2012
    PubMed: PMID 22285168 · NCT00446225 (EURTAC) · Carcinoma, Non-Small-Cell Lung
  4. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
    Redig AJ, Costa DB, Taibi M, et al. · JAMA Oncol · 2017
    PubMed: PMID 27387964 · NCT00997334 · Carcinoma, Non-Small-Cell Lung
  5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M, Inoue A, Kobayashi K, et al. · N Engl J Med · 2010
    PubMed: PMID 20573926 · NCT02759614
  6. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ, Gadgeel SM, Borghaei H, et al. · Lancet Oncol · 2017
    PubMed: PMID 27745820 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  7. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW, Higano CS, Shore ND, et al. · N Engl J Med · 2010
    PubMed: PMID 20818862 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  8. Cancer stem cells.
    Jordan CT, Guzman ML, Noble M, et al. · N Engl J Med · 2006
    PubMed: PMID 16990388 · NCT07271446 · Carcinoma, Non-Small-Cell Lung

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00096265Carcinoma, Non-Small-Cell LungOverall Survival
From randomization to date of death or last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
Erlotinib + WBRT + SRS6.1 months
Temozolomide + WBRT + SRS6.3 months
WBRT + SRS13.4 months
NCT00130728Carcinoma, Non-Small-Cell LungOverall Survival (OS) Among All Randomized Patients
From the date of randomization until the date of patient death from any cause, or the date of last contact. (Up to 3.1 years)
Erlotinib HCl + Bevacizumab9.3 months
Erlotinib HCl + Placebo9.2 months
NCT00153803Carcinoma, Non-Small-Cell LungProgression Free Survival
5 years
Placebo8.1 Months
Tarceva7.4 Months
NCT00257608Carcinoma, Non-Small-Cell LungProgression-free Survival (PFS)
Approximately 3 years
Bevacizumab + Erlotinib4.8 months
Bevacizumab + Placebo3.7 months
NCT00364351Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS)
progressionRECIST tumour assessments carried out every 4 weeks up to week 16 then every 8 weeks thereafter from randomisation until the date of first documented objective disease progression or date of death from any cause, whichever came first, assessed.
Erlotinib8.9 Weeks
Vandetanib11.3 Weeks
NCT00373425
RADIANT
Carcinoma, Non-Small-Cell LungDisease Free Survival (DFS)
Every 3 months during active phase and every 6 months during long term follow-up up to 5 years and yearly thereafter until the data cutoff date of 11 June 2014 (maximum time on follow-up was 78 months).
Erlotinib55.0 months
Erlotinib55.0 months
Erlotinib50.5 months
Erlotinib50.5 months
Placebo56.2 months
Placebo56.2 months
Placebo48.2 months
Placebo48.2 months
NCT00402779Mouth NeoplasmsOral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group.
3 years
Erlotinib55 Participants
Placebo18 Participants
NCT00412217Head and Neck NeoplasmsNumber of Participants With Disease Progression
From inclusion in the study until disease progression (maximum up to 3 years overall)
Erlotinib15 participants
Placebo11 participants
NCT00412217Head and Neck NeoplasmsTime to Progression (TTP)
From inclusion in the study until disease progression, appearance of second tumor, or death from any cause (maximum up to 3 years overall)
ErlotinibNA months
PlaceboNA months
NCT00446225
EURTAC
Carcinoma, Non-Small-Cell LungProgression Free-survival
From the date of randomization to the date of last follow up, assessed up to 24 months
A: Erlotinib Group9.4 months
B: Standard Chemotherapy Group5.2 months
NCT00448240Head and Neck NeoplasmsTumor Response Rate of Intermittent Tarceva During First Line Standard Platinum Containing Chemotherapy
Evaluated at 6-week intervals, up to an average of 18 weeks.
Erlotinib2 Participants
Erlotinib1 Participants
Erlotinib3 Participants
NCT00457392Carcinoma, Non-Small-Cell LungOverall Survival (OS)
Baseline to death or 28 days after last dose for the last participant
Erlotinib8.5 Months
Sunitinib + Erlotinib9.0 Months
NCT00556322Carcinoma, Non-Small-Cell LungDuration of Overall Survival in All Participants (Data Cutoff 07 September 2010)
Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 and Every 12 Weeks until Death or Until Data Cut off (07 September 2010) up to 52 months
Comparator5.5 months
Erlotinib5.3 months
NCT00556322Carcinoma, Non-Small-Cell LungPercentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010)
Baseline, Weeks 3 and 6, Every 3 Weeks until Week 48 or Death and Every 12 Weeks until Death or Data Cut off (07 September 2010) up to 52 months
Comparator81.0 percentage of participants
Erlotinib77.8 percentage of participants
NCT00556322Carcinoma, Non-Small-Cell LungProbable Percentage of Participants Remaining Alive at 1 Year
1 Year
Comparator24.0 percentage of participants
Erlotinib26.0 percentage of participants
NCT00556712Carcinoma, Non-Small-Cell LungPercentage of Epidermal Growth Factor Receptor (EGFR) Immunohistochemistry (IHC) Positive Participants With PD or Death (Data Cutoff 17 May 2008)
Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Erlotinib, 150 mg/Day79.5 percentage of participants
Placebo89.4 percentage of participants
NCT00556712Carcinoma, Non-Small-Cell LungPercentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008)
Screening, BL [≤21 days after randomization], every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Erlotinib, 150 mg/Day79.9 percentage of participants
Placebo89.5 percentage of participants
NCT00556712Carcinoma, Non-Small-Cell LungPFS in All Participants (Data Cutoff 17 May 2008)
Screening, BL (≤21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Erlotinib, 150 mg/Day12.3 weeks
Placebo11.1 weeks
NCT00556712Carcinoma, Non-Small-Cell LungPFS in EGFR IHC Positive Population (Data Cutoff 17 May 2008)
Screening, BL (≤ 21 days after randomization), every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)
Erlotinib, 150 mg/Day12.3 weeks
Placebo11.1 weeks
NCT00556712Carcinoma, Non-Small-Cell LungProbable Percentage of Participants in the EGFR IHC Positive Population Remaining Alive and Progression Free at 6 Months (Data Cutoff 17 May 2008)
6 months
Erlotinib, 150 mg/Day27.0 percentage of participants
Placebo16.0 percentage of participants
NCT00556712Carcinoma, Non-Small-Cell LungProbable Percentage of Participants Remaining Alive and Free of Disease Progression at 6 Months (Data Cutoff 17 May 2008)
6 months
Erlotinib, 150 mg/Day25.0 percentage of participants
Placebo15.0 percentage of participants
NCT00673049
NSCLC
Carcinoma, Non-Small-Cell LungOverall Survival
Baseline, assessed every cycle until disease progression and then every 4 weeks until death, up to 30.65 months
Erlotinib6.2 months
Figitumumab + Erlotinib5.7 months
NCT00718315Carcinoma, Non-Small-Cell LungPercentage of Participants Who Develop Skin Rash
30 Days
Fisiogel60.0 percentage of participants
Stiemicyn69.2 percentage of participants
Verutex73.1 percentage of participants
NCT00718315Carcinoma, Non-Small-Cell LungPercentage of Participants With Skin Rash Stratified by Severity Grade
30 Days
Fisiogel29.8 percentage of participants
Fisiogel0 percentage of participants
Fisiogel0 percentage of participants
Fisiogel0 percentage of participants
Fisiogel49.1 percentage of participants
Fisiogel21.1 percentage of participants
Stiemicyn56.7 percentage of participants
Stiemicyn0 percentage of participants
Stiemicyn25.0 percentage of participants
Stiemicyn0 percentage of participants
Stiemicyn0 percentage of participants
Stiemicyn18.3 percentage of participants
Verutex43.3 percentage of participants
Verutex35.0 percentage of participants
Verutex3.3 percentage of participants
Verutex18.3 percentage of participants
Verutex0 percentage of participants
Verutex0 percentage of participants
NCT00738881
MARVEL
Carcinoma, Non-Small-Cell LungProgression-free Survival (PFS)
Time from randomization to the first date of documented disease progression or death, assessed up to 5 years
Arm I2 months
Arm II3.1 months
NCT00883779—Median Progression Free Survival (PFS) Time
Randomization until PD or death (assessed at baseline and every 8 weeks thereafter until PD, death or end of study [up to approximately 1.5 years])
Erlotinib7.6 months
Placebo6.0 months
NCT00901901
SEARCH
Carcinoma, HepatocellularOverall Survival
From randomization of the first patient until 34 months or date of death of any cause whichever came first
Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)289 Days
Sorafenib (Nexavar, BAY43-9006) + Placebo259 Days
NCT01013649Pancreatic Intraductal NeoplasmsOverall Survival (Percentage of Participants Alive) [Phase II]
From step 1 randomization (gemcitabine vs. gemcitabine/erlotinib) to death or last follow-up. Maximum follow-up at the time of the phase II analysis was 6.2 years.
Arm I (Gemcitabine Hydrochloride or Combination Chemotherapy)29.9 months
Arm II (Gemcitabine Hydrochloride, Erlotinib Hydrochloride)28.1 months
NCT01013649Pancreatic Intraductal NeoplasmsOverall Survival (Percentage of Participants Alive) [Phase III]
From step 2 randomization (chemotherapy vs. chemotherapy followed by chemoradiation) to the date of death or last follow-up. Maximum follow-up at time of the phase III analysis was 12.8 years, measured from step 2 randomization.
Arm III (Chemotherapy)31.1 months
Arm IV (Chemotherapy, Chemoradiotherapy)27.3 months
NCT01183858Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS)
Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 Months)
Erlotinib 150 mg6.86 weeks
Erlotinib 300 mg7.00 weeks
NCT01183858Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS) at the End of Study
Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months)
Erlotinib 150 mg6.86 weeks
Erlotinib 300 mg7.00 weeks
NCT01244191Carcinoma, Non-Small-Cell LungOverall Survival Following Treatment With Tivantinib (ARQ 197) Plus Erlotinib Compared to Placebo Plus Erlotinib in Previously Treated Participants With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer
Date of randomization up to date of death, up to approximately 1 year 11 months postdose
Placebo and Erlotinib7.8 months
Tivantinib and Erlotinib8.5 months
NCT01328951—Overall Survival (OS) as Median Time to Event During the Overall Study
Up to approximately 3.5 years (visits at Baseline and Weeks 6, 12, and 18 and every 12 weeks until/at disease progression during BP; per local standards during OLP; then every 12 weeks during SFU until death)
Early Erlotinib9.72 months
Late Erlotinib9.46 months
NCT01328951—Percentage of Participants Event-Free (Alive) at 1 Year During the Overall Study
At 1 year
Early Erlotinib42.15 percentage of participants
Late Erlotinib41.75 percentage of participants
NCT01328951—Percentage of Participants Who Died During the Overall Study
Up to approximately 3.5 years (visits at Baseline and Weeks 6, 12, and 18 and every 12 weeks until/at disease progression during BP; per local standards during OLP; then every 12 weeks during SFU until death)
Early Erlotinib75.2 percentage of participants
Late Erlotinib73.2 percentage of participants
NCT01342965Carcinoma, Non-Small-Cell LungInvestigator-assessed Duration of Progression-free Survival
Baseline to the data cut-off date of 20 Jul 2012 (1 year, 4 months)
Chemotherapy5.5 Months
Erlotinib11.0 Months
NCT01351415—Overall Survival (OS)
Up to data cut-off date 24 June 2016 (approximately 5 years)
Bevacizumab + Standard of Care11.86 Months
Standard of Care10.22 Months
NCT01360554
ARCHER 1009
Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.
Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)2.6 Months
Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)2.5 Months
NCT01360554
ARCHER 1009
Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS) Per Independent Radiologic Review.
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.
Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)2.6 Months
Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)2.5 Months
NCT01523587Carcinoma, Non-Small-Cell LungProgression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1
First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).
Afatinib2.63 Months
Erlotinib1.94 Months
NCT01652469
EMPHASIS
Carcinoma, Non-Small-Cell LungProgression-free Survival
The combined run in period, treatment and follow-up for PFS is expected to extend the study duration to a total of 24 months.
A: Erlotinib1.6 months
B: Docetaxel3.0 months
NCT01667562
ESSENCE
Carcinoma, Non-Small-Cell LungProgression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1)
Baseline until disease progression, or death, whichever occurs first (approximately up to 4 years and 9 months)
Erlotinib9.574 months
NCT02134015
HER3-Lung
Carcinoma, Non-Small-Cell LungPart A: Progression Free Survival (PFS) in Heregulin-high Participants
by trial termination (at 20 months)
Patritumab + Erlotinib1.9 months
Placebo + Erlotinib2.7 months
NCT02134015
HER3-Lung
Carcinoma, Non-Small-Cell LungPart A: Progression Free Survival (PFS) in Heregulin-low Participants
by trial termination (at 20 months)
Patritumab + Erlotinib1.5 months
Placebo + Erlotinib2.8 months
NCT02152631
JUNIPER
Carcinoma, Non-Small-Cell LungOverall Survival (OS)
From Randomization Date to Date of Death from Any Cause (Up to 32 Months)
Abemaciclib7.4 months
Erlotinib7.8 months
NCT02186301
EGFR
Carcinoma, Non-Small-Cell LungProgression Free Survival (PFS) According to RECIST Version 1.1 as Determined by Investigator Review (invPFS)
Cycle 1 Day 1 to End of Treatment, up to approximately 35 months
Erlotinib 150mg Tablets390 Days
Rociletinib 500mg Tablets274 Days
Rociletinib 625mg Tablets207 Days
NCT02296125
FLAURA
—Median Progression Free Survival (PFS) (Months)
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
Osimertinib 80 mg (China Cohort)17.8 Months
Osimertinib 80 mg (Global Cohort)18.9 Months
SoC EGFR-TKI (China Cohort)9.8 Months
SoC EGFR-TKI (Global Cohort)10.2 Months
NCT02296125
FLAURA
—Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
Osimertinib 80 mg (China Cohort)67.3 Percentage of Participants
Osimertinib 80 mg (China Cohort)46.9 Percentage of Participants
Osimertinib 80 mg (China Cohort)78.8 Percentage of Participants
Osimertinib 80 mg (Global Cohort)50.9 Percentage of Participants
Osimertinib 80 mg (Global Cohort)88.4 Percentage of Participants
Osimertinib 80 mg (Global Cohort)68.2 Percentage of Participants
SoC EGFR-TKI (China Cohort)25.8 Percentage of Participants
SoC EGFR-TKI (China Cohort)44.6 Percentage of Participants
SoC EGFR-TKI (China Cohort)72.3 Percentage of Participants
SoC EGFR-TKI (Global Cohort)42.3 Percentage of Participants
SoC EGFR-TKI (Global Cohort)75.2 Percentage of Participants
SoC EGFR-TKI (Global Cohort)24.4 Percentage of Participants
NCT02352948
ARCTIC
—Overall Survival (OS)
From randomization (Day 1) until death due to any cause, approximately 36 months
Sub-study A: Durvalumab11.7 months
Sub-study A: SoC6.8 months
Sub-study B: Durvalumab+Tremelimumab11.5 months
Sub-study B: SoC8.7 months
NCT02352948
ARCTIC
—Progression-Free Survival (PFS)
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Sub-study A: Durvalumab3.8 months
Sub-study A: SoC2.2 months
Sub-study B: Durvalumab+Tremelimumab3.5 months
Sub-study B: SoC3.5 months
NCT02411448
RELAY
Carcinoma, Non-Small-Cell LungNumber of Participants With Treatment-Emergent Adverse Events
Cycle 1 Day 1 through End of Study (Up To 3 Years)
Part A: Ramucirumab + Erlotinib14 Participants
Part B: Placebo + Erlotinib225 Participants
Part B: Ramucirumab + Erlotinib221 Participants
NCT02411448
RELAY
Carcinoma, Non-Small-Cell LungPart B: Progression Free Survival (PFS)
Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)
Part B: Placebo+ Erlotinib12.4 Months
Part B: Ramucirumab+ Erlotinib19.4 Months
NCT02488330—Percentage of Participants With Serious Adverse Events Considered Related to Onartuzumab
Baseline through the end of trial (approximately 3 years)
Control and/or Onartuzumab Treatment0 Percent
NCT02588261
SOLAR
Carcinoma, Non-Small-Cell LungProgression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR)
From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months)
ASP82739.26 months
Erlotinib or Gefitinib9.59 months
NCT02694536Pancreatic NeoplasmsPercentage of Participants With Adverse Events (AEs)
Up to approximately 40 months (assessed continuously during treatment)
Erlotinib + Gemcitabine78.8 percentage of participants

Publications by year

1971–2026: 646 publications.

1971
1
1975
1
1978
1
1983
1
1986
1
1987
1
1989
2
1990
2
1992
1
1993
4
1994
2
1995
6
1996
4
1997
7
1998
3
1999
6
2000
10
2001
14
2002
10
2003
19
2004
26
2005
39
2006
22
2007
24
2008
23
2009
17
2010
20
2011
26
2012
30
2013
37
2014
35
2015
34
2016
43
2017
16
2018
10
2019
24
2020
22
2021
18
2022
29
2023
21
2024
13
2025
14
2026
7

Publications by indication

Carcinoma, Non-Small-Cell Lung (312)

  • Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset.
    JTO Clin Res Rep · 2026 · PMID 40458541 · NCT02411448
  • The role of the molecular tumor board: learnings from the ROME trial.
    NPJ Precis Oncol · 2026 · PMID 41963505 · NCT04591431
  • Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.
    J Cachexia Sarcopenia Muscle · 2026 · PMID 42126170 · NCT01360554
  • First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
    Med · 2025 · PMID 39389055 · NCT03653546
  • Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases.
    Transl Lung Cancer Res · 2025 · PMID 39830774 · NCT01887795

Lung Neoplasms (34)

  • Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.
    Front Oncol · 2022 · PMID 34970476 · NCT01024413
  • Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.
    Clin Cancer Res · 2021 · PMID 32144133 · NCT01556191
  • Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
    J Thorac Oncol · 2021 · PMID 33524601 · NCT03628521
  • A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    BMC Cancer · 2018 · PMID 28264648 · NCT00600496
  • A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
    Invest New Drugs · 2018 · PMID 28424891 · NCT00600496

Neoplasms (31)

  • Prospective evaluation of genomics-guided off-label treatment.
    Nature · 2026 · PMID 41986720 · NCT02925234
  • Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
    Front Oncol · 2026 · PMID 36910668 · NCT03239015
  • MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
    J Clin Oncol · 2024 · PMID 37793085 · NCT02091141
  • Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial.
    Front Oncol · 2024 · PMID 39148905 · NCT02714530
  • Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Clin Cancer Res · 2024 · PMID 38630551 · NCT02925234

Pancreatic Neoplasms (26)

  • Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Semin Cancer Biol · 2025 · PMID 39863139 · NCT02737228
  • TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.
    Br J Cancer · 2023 · PMID 37142730 · NCT00440167
  • Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
    Br J Cancer · 2021 · PMID 32830200 · NCT00440167
  • Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
    BMC Cancer · 2020 · PMID 32093649 · NCT01782690
  • A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Oncologist · 2020 · PMID 30679315 · NCT00550836

Esophageal Neoplasms (21)

  • A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.
    Clin Adv Hematol Oncol · 2013 · PMID 22895283 · NCT00393068
  • Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
    J Clin Oncol · 2006 · PMID 17050876 · NCT00032123
  • Targeted therapies for esophageal cancer.
    Oncologist · 2006 · PMID 16177283 · NCT00442507
  • Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Clin Cancer Res · 2005 · PMID 16166415 · NCT00442507
  • Cancer statistics, 2005.
    CA Cancer J Clin · 2005 · PMID 15661684 · NCT00442507

Squamous Cell Carcinoma of Head and Neck (15)

  • Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.
    Head Neck · 2025 · PMID 40166973 · NCT01316757
  • Enhancing transcription-replication conflict targets ecDNA-positive cancers.
    Nature · 2024 · PMID 39506153 · NCT05827614
  • A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
    Clin Cancer Res · 2023 · PMID 36378548 · NCT05827614
  • Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status.
    Front Oncol · 2022 · PMID 36110959 · NCT00601913
  • Extrachromosomal DNA: An Emerging Hallmark in Human Cancer.
    Annu Rev Pathol · 2022 · PMID 34752712 · NCT05827614

Publications by journal

  • J Clin Oncol85 papers
  • Clin Cancer Res36 papers
  • Ann Oncol28 papers
  • Lancet Oncol24 papers
  • Lung Cancer20 papers
  • N Engl J Med19 papers
  • J Thorac Oncol19 papers
  • Cancer Chemother Pharmacol16 papers
  • Eur J Cancer16 papers
  • Clin Lung Cancer15 papers

Trial-results highlights

In studies for Non-Small-Cell Lung Carcinoma, overall survival and disease-free survival outcomes were reported. In NCT00096265, which followed patients for up to 48.1 months, median Overall Survival was:

  • Erlotinib + WBRT + SRS: 6.1 months
  • Temozolomide + WBRT + SRS: 6.3 months
  • WBRT + SRS: 13.4 months

For NCT00130728, assessing Overall Survival for up to 3.1 years, the Erlotinib HCl + Bevacizumab arm reported a median of 9.3 months, while the Erlotinib HCl + Placebo arm reported 9.2 months. In NCT00373425 (RADIANT), with follow-up up to 78 months, Disease Free Survival median values were:

  • For Erlotinib: 55.0 months and 50.5 months
  • For Placebo: 56.2 months

Progression-free survival was also evaluated in Non-Small-Cell Lung Carcinoma studies. In NCT00153803, which followed patients for 5 years, the Tarceva arm reported a median Progression Free Survival of 7.4 Months, compared to 8.1 Months for the Placebo arm. In NCT00257608, assessing Progression-free Survival for approximately 3 years, the Bevacizumab + Erlotinib arm reported a median of 4.8 months, while the Bevacizumab + Placebo arm reported 3.7 months. For NCT00364351, median Progression-Free Survival was 8.9 Weeks for the Erlotinib arm and 11.3 Weeks for the Vandetanib arm.

For other indications, NCT00402779, a study in Mouth Neoplasms followed for 3 years, reported 55 Participants in the Erlotinib arm and 18 Participants in the Placebo arm for Oral Cancer-free Survival. In NCT00412217, a study in Head and Neck Neoplasms followed for up to 3 years, the number of participants with disease progression was 15 participants in the Erlotinib arm and 11 participants in the Placebo arm. All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Erlotinib publications (646)

2026 (7 papers)

  1. Prospective evaluation of genomics-guided off-label treatment.
    Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
    PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
  2. Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy.
    Tanabe KK, Zahrieh D, Strand CA, et al. · Gastro Hep Adv · 2026 · Derived
    PubMed: PMID 39131140 · NCT02273362 · Carcinoma, Hepatocellular
  3. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset.
    Nishio M, Seto T, Reck M, et al. · JTO Clin Res Rep · 2026 · Derived
    PubMed: PMID 40458541 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  4. The role of the molecular tumor board: learnings from the ROME trial.
    Marchetti P, Curigliano G, Westphalen CB, et al. · NPJ Precis Oncol · 2026 · Derived
    PubMed: PMID 41963505 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
  5. Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
    Jiao XD, Qin BD, Wang Z, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 36910668 · NCT03239015 · Neoplasms
  6. Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.
    Debily MA, Le Teuff G, Kergrohen T, et al. · Nat Med · 2026 · Derived
    PubMed: PMID 42032072 · NCT02233049 (BIOMEDE) · Diffuse Intrinsic Pontine Glioma
  7. Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies.
    Breen DM, Joaquim S, Paulhus BL, et al. · J Cachexia Sarcopenia Muscle · 2026 · Derived
    PubMed: PMID 42126170 · NCT01360554 (ARCHER 1009) · Carcinoma, Non-Small-Cell Lung

2025 (14 papers)

  1. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
    Zhou Q, Yu Y, Xing L, et al. · Med · 2025 · Trial result
    PubMed: PMID 39389055 · NCT03653546 (BM) · Carcinoma, Non-Small-Cell Lung
  2. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT02737228 · Pancreatic Neoplasms
  3. Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases.
    Tang F, Zhang J, Xu Z, et al. · Transl Lung Cancer Res · 2025 · Derived
    PubMed: PMID 39830774 · NCT01887795 · Carcinoma, Non-Small-Cell Lung
  4. Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.
    Srinivasan R, Gurram S, Singer EA, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40532152 · NCT01130519 · Carcinoma, Renal Cell
  5. Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
    Sacher AG, Miller WH, Patel MR, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40632992 · NCT04449874 · Carcinoma, Non-Small-Cell Lung
  6. Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.
    Occhipinti M, Imbimbo M, Ferrara R, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40421698 · NCT01683175 · Carcinoma, Non-Small-Cell Lung
  7. RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC.
    Nishino K, Seto T, Nishio M, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40995949 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  8. RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
    Nakagawa K, Garon EB, Seto T, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39622410 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  9. EGFR mutation testing across the osimertinib clinical program.
    Murat-Onana ML, Ramalingam SS, Jänne PA, et al. · Lung Cancer · 2025 · Derived
    PubMed: PMID 40311309 · NCT02296125 (FLAURA)
  10. A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC.
    Mishina A, Zhudenkov K, Helmlinger G, et al. · CPT Pharmacometrics Syst Pharmacol · 2025 · Derived
    PubMed: PMID 40785488 · NCT00364351 · Carcinoma, Non-Small-Cell Lung
  11. Variability of Circulating Tumor DNA Levels in Plasma Samples From Patients With Advanced Non-Small-Cell Lung Cancer in the Absence of Treatment.
    Markovets A, Merino Vega D, Abbosh C, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41166679 · NCT02296125 (FLAURA)
  12. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
    Marchetti P, Curigliano G, Biffoni M, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41023484 · NCT04591431 (ROME) · Carcinoma, Non-Small-Cell Lung
  13. Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up.
    Kim P, Saba NF, McCook-Veal A, et al. · Head Neck · 2025 · Derived
    PubMed: PMID 40296503 · NCT00400374 · Head and Neck Neoplasms
  14. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.
    Bhatia A, Mehra R, Bauman J, et al. · Head Neck · 2025 · Derived
    PubMed: PMID 40166973 · NCT01316757 · Squamous Cell Carcinoma of Head and Neck

2024 (13 papers)

  1. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
    Weiss L, Heinemann V, Fischer LE, et al. · Clin Transl Oncol · 2024 · Derived
    PubMed: PMID 37794220 · NCT01729481 (ML22774)
  2. A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.
    Viray H, Piper-Vallillo AJ, Widick P, et al. · Cancers (Basel) · 2024 · Derived
    PubMed: PMID 38539415 · NCT02296125 (FLAURA)
  3. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
    Sweeney CJ, Hainsworth JD, Bose R, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 37793085 · NCT02091141 · Neoplasms
  4. Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial.
    Nymoen HM, Alver TN, Horndalsveen H, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 39148905 · NCT02714530 (ThoRaT) · Neoplasms
  5. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
    Krämer A, Bochtler T, Pauli C, et al. · Lancet · 2024 · Derived
    PubMed: PMID 39096924 · NCT03498521 (CUPISCO) · Neoplasms, Unknown Primary
  6. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
    Kozono D, Hua X, Wu MC, et al. · J Thorac Oncol · 2024 · Derived
    PubMed: PMID 39111731 · NCT02154490
  7. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
    Kim SY, Kim JH, Kim TY, et al. · BMC Cancer · 2024 · Derived
    PubMed: PMID 38724991 · NCT05525858 (KOSMOSII) · Neoplasm Metastasis
  8. Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
    Johnson M, Serra Traynor C, Vishwanathan K, et al. · Clin Pharmacol Ther · 2024 · Derived
    PubMed: PMID 38010260 · NCT02296125 (FLAURA)
  9. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Review and Guidelines.
    Jethwa KR, Kim E, Berlin J, et al. · Am J Clin Oncol · 2024 · Derived
    PubMed: PMID 38131628 · NCT01013649 · Pancreatic Intraductal Neoplasms
  10. Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3.
    Gray JE, Markovets A, Reungwetwattana T, et al. · J Thorac Oncol · 2024 · Derived
    PubMed: PMID 39029876 · NCT02296125 (FLAURA)
  11. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
  12. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
    Desai J, Alonso G, Kim SH, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38052910 · NCT04449874 · Carcinoma, Non-Small-Cell Lung
  13. Enhancing transcription-replication conflict targets ecDNA-positive cancers.
    Tang J, Weiser NE, Wang G, et al. · Nature · 2024 · Background
    PubMed: PMID 39506153 · NCT05827614 (POTENTIATE) · Squamous Cell Carcinoma of Head and Neck

2023 (21 papers)

  1. Mechanisms of resistance to EGFR-targeted drugs: lung cancer.
    Morgillo F, Della Corte CM, Fasano M, et al. · ESMO Open · 2023 · Trial result
    PubMed: PMID 27843613 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.
    Zhong WZ, Yan HH, Chen KN, et al. · Signal Transduct Target Ther · 2023 · Derived
    PubMed: PMID 36823150 · NCT01407822 (EMERGING) · Carcinoma, Non-Small-Cell Lung
  3. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
  4. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
    Stone JK, Mehta NA, Singh H, et al. · Fam Cancer · 2023 · Derived
    PubMed: PMID 37119510 · NCT02961374 · Adenomatous Polyposis Coli
  5. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    Stinchcombe TE, Jänne PA, Wang X, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 31393548 · NCT01532089
  6. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Samadder NJ, Foster N, McMurray RP, et al. · Gut · 2023 · Derived
    PubMed: PMID 35636921 · NCT02961374 · Adenomatous Polyposis Coli
  7. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
    Saltos AN, Creelan BC, Tanvetyanon T, et al. · Lung Cancer · 2023 · Derived
    PubMed: PMID 37499521 · NCT01859026 · Carcinoma, Non-Small-Cell Lung
  8. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
    Sacher A, LoRusso P, Patel MR, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37611121 · NCT04449874 · Carcinoma, Non-Small-Cell Lung
  9. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).
    Reckamp KL, Frankel PH, Ruel N, et al. · Front Oncol · 2023 · Derived
    PubMed: PMID 30915273 · NCT01866410 · Carcinoma, Non-Small-Cell Lung
  10. Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
    Qin BD, Jiao XD, Wang Z, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37155342 · NCT03239015 · Neoplasms
  11. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).
    Nishio K, Sakai K, Nishio M, et al. · Transl Lung Cancer Res · 2023 · Derived
    PubMed: PMID 37691865 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  12. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
    Kringelbach T, Højgaard M, Rohrberg K, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36814246 · NCT04341181 (ProTarget) · Neoplasms
  13. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.
    Guenther M, Surendran SA, Haas M, et al. · Br J Cancer · 2023 · Derived
    PubMed: PMID 37142730 · NCT00440167 · Pancreatic Neoplasms
  14. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
  15. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
    Garon EB, Reck M, Nishio K, et al. · ESMO Open · 2023 · Derived
    PubMed: PMID 37390764 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  16. Adjuvant and neoadjuvant approaches in pancreatic cancer.
    Conroy T, Lambert A, Ducreux M, et al. · Curr Opin Oncol · 2023 · Derived
    PubMed: PMID 37222189 · NCT01013649 · Pancreatic Intraductal Neoplasms
  17. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
    Chiu CH, Lin MC, Wei YF, et al. · Target Oncol · 2023 · Derived
    PubMed: PMID 37329423 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  18. Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia.
    Cheng Y, Yang JC, Okamoto I, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 37465924 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  19. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
    Camidge DR, Barlesi F, Goldman JW, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36288547 · NCT02099058 · Neoplasms
  20. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
    Aldin A, Besiroglu B, Adams A, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37146227 · NCT00081614 · Neoplasm Metastasis
  21. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
    Jones R, Plummer R, Moreno V, et al. · Clin Cancer Res · 2023 · Background
    PubMed: PMID 36378548 · NCT05827614 (POTENTIATE) · Squamous Cell Carcinoma of Head and Neck

2022 (29 papers)

  1. Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
    Yue D, Xu S, Wang Q, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 36027483 · NCT01683175 · Carcinoma, Non-Small-Cell Lung
  2. Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.
    Yu YF, Luan L, Zhu FF, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 34970476 · NCT01024413 · Lung Neoplasms
  3. Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions.
    Walding A, Skaltsa K, Casamayor M, et al. · Qual Life Res · 2022 · Derived
    PubMed: PMID 35099678 · NCT02296125 (FLAURA)
  4. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
    van Linde ME, Labots M, Brahm CG, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35165100 · NCT02239952 · Neoplasms
  5. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
    van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
  6. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
    Subbiah V, Dumbrava EI, Jiang Y, et al. · Exp Hematol Oncol · 2022 · Derived
    PubMed: PMID 32337094 · NCT00543504
  7. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
    Riess JW, Reckamp KL, Frankel P, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 34140248 · NCT02535338 · Carcinoma, Non-Small-Cell Lung
  8. Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status.
    Porosnicu M, O'Brien Cox A, Waltonen JD, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 36110959 · NCT00601913 · Squamous Cell Carcinoma of Head and Neck
  9. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
    Popat S, Hsia TC, Hung JY, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35274704 · NCT04179890 (UpSwinG) · Carcinoma, Non-Small-Cell Lung
  10. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
    Piccirillo MC, Bonanno L, Garassino MC, et al. · J Thorac Oncol · 2022 · Derived
    PubMed: PMID 35659580 · NCT02633189 (BEVERLY)
  11. Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
    Patnaik A, Gadgeel S, Papadopoulos KP, et al. · Target Oncol · 2022 · Derived
    PubMed: PMID 35347559 · NCT00975767 · Carcinoma, Non-Small-Cell Lung
  12. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
    Padda SK, Reckamp KL, Koczywas M, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 34773474 · NCT02206763
  13. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.
    Nishio M, Nishio K, Reck M, et al. · JTO Clin Res Rep · 2022 · Derived
    PubMed: PMID 35369607 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  14. Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm.
    Narita Y, Yoshimoto T, Namai T, et al. · JCO Clin Cancer Inform · 2022 · Derived
    PubMed: PMID 35649212 · NCT02091141 · Neoplasms
  15. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
  16. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
    Nakagawa K, Garon EB, Gao L, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35841410 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  17. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
    Nadal E, Horinouchi H, Shih JY, et al. · Drug Saf · 2022 · Derived
    PubMed: PMID 34928484 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  18. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
    Mattes MD, Eubank TD, Almubarak M, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 33608212 · NCT03137771 · Carcinoma, Non-Small-Cell Lung
  19. How patients being treated for non-small cell lung cancer value treatment benefit despite side effects.
    Martin ML, Correll J, Walding A, et al. · Qual Life Res · 2022 · Derived
    PubMed: PMID 34056687 · NCT02352948 (ARCTIC)
  20. Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
    Lu S, Li W, Zhou C, et al. · Onco Targets Ther · 2022 · Derived
    PubMed: PMID 30573970 · NCT01523587 · Carcinoma, Non-Small-Cell Lung
  21. Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial.
    Lin J, Li M, Chen S, et al. · J Inflamm Res · 2022 · Derived
    PubMed: PMID 34168480 · NCT02886195 (effect)
  22. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
    Kehl KL, Zahrieh D, Yang P, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 35297944 · NCT02194738 · Carcinoma, Non-Small-Cell Lung
  23. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
    Goldman JW, Mazieres J, Barlesi F, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 33194700 · NCT02152631 (JUNIPER) · Carcinoma, Non-Small-Cell Lung
  24. Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
    Friedman CF, Hainsworth JD, Kurzrock R, et al. · Cancer Discov · 2022 · Derived
    PubMed: PMID 34876409 · NCT02091141 · Neoplasms
  25. A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.
    Feng Z, Curti BD, Quinn DI, et al. · Clin Genitourin Cancer · 2022 · Derived
    PubMed: PMID 35688679 · NCT00425386 · Carcinoma, Renal Cell
  26. Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study.
    Chen Z, Shen S, Shi W, et al. · Cancer Manag Res · 2022 · Derived
    PubMed: PMID 31372055 · NCT01297101 · Carcinoma, Non-Small-Cell Lung
  27. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
    Camidge DR, Morgensztern D, Heist RS, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34426443 · NCT02099058 · Neoplasms
  28. Extrachromosomal DNA: An Emerging Hallmark in Human Cancer.
    Wu S, Bafna V, Chang HY, et al. · Annu Rev Pathol · 2022 · Background
    PubMed: PMID 34752712 · NCT05827614 (POTENTIATE) · Squamous Cell Carcinoma of Head and Neck
  29. The evolutionary dynamics of extrachromosomal DNA in human cancers.
    Lange JT, Rose JC, Chen CY, et al. · Nat Genet · 2022 · Background
    PubMed: PMID 36123406 · NCT05827614 (POTENTIATE) · Squamous Cell Carcinoma of Head and Neck

2021 (18 papers)

  1. Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study.
    Witlox WJA, Ramaekers BLT, Joore MA, et al. · Radiother Oncol · 2021 · Trial result
    PubMed: PMID 31733490 · NCT00835471 (NVALT10) · Carcinoma, Non-Small-Cell Lung
  2. Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
    Assenat E, Mineur L, Mollevi C, et al. · Int J Cancer · 2021 · Trial result
    PubMed: PMID 33405269 · NCT01204372 (GATE 1)
  3. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.
    Yang Z, Zhang Y, Li R, et al. · Neuro Oncol · 2021 · Derived
    PubMed: PMID 33331923 · NCT01887795 · Carcinoma, Non-Small-Cell Lung
  4. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.
    Xiong L, Lou Y, Bai H, et al. · J Int Med Res · 2021 · Derived
    PubMed: PMID 31885349 · NCT01217619 (ML25444) · Carcinoma, Non-Small-Cell Lung
  5. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33125909 · NCT02154490
  6. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
    Planchard D, Reinmuth N, Orlov S, et al. · Ann Oncol · 2021 · Derived
    PubMed: PMID 32201234 · NCT02352948 (ARCTIC)
  7. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
    Park H, Williams K, Trikalinos NA, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33159216 · NCT00770263
  8. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
    Ou SI, Gadgeel SM, Barlesi F, et al. · Lung Cancer · 2021 · Derived
    PubMed: PMID 31706099 · NCT01801111 · Carcinoma, Non-Small-Cell Lung
  9. Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach.
    Mitani S, Chen Y, Inoue K, et al. · Gan To Kagaku Ryoho · 2021 · Derived
    PubMed: PMID 34795131 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  10. Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.
    Mazieres J, Barlesi F, Rouquette I, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 32144133 · NCT01556191 (LADIE) · Lung Neoplasms
  11. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
    Javle M, Borad MJ, Azad NS, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34339623 · NCT02091141 · Neoplasms
  12. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
    Guenther M, Haas M, Heinemann V, et al. · Br J Cancer · 2021 · Derived
    PubMed: PMID 32830200 · NCT00440167 · Pancreatic Neoplasms
  13. Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment.
    Gong K, Guo G, Beckley N, et al. · Neoplasia · 2021 · Derived
    PubMed: PMID 33373873 · NCT00410059 · Carcinoma, Non-Small-Cell Lung
  14. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
    Deng Z, Qin Y, Liu Y, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33067126 · NCT02655536 (BRILLIANT) · Carcinoma, Non-Small-Cell Lung
  15. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
    Chu T, Zhong R, Zhong H, et al. · J Thorac Oncol · 2021 · Derived
    PubMed: PMID 33524601 · NCT03628521 · Lung Neoplasms
  16. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y, He Y, Li W, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 33544337 · NCT02296125 (FLAURA)
  17. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.
    Brown H, Vansteenkiste J, Nakagawa K, et al. · J Thorac Oncol · 2021 · Derived
    PubMed: PMID 31605792 · NCT02296125 (FLAURA)
  18. Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma: A Single-Institution Experience.
    Batukbhai B, Herman JM, Zahurak M, et al. · Pancreas · 2021 · Derived
    PubMed: PMID 33370024 · NCT01013649 · Pancreatic Intraductal Neoplasms

2020 (22 papers)

  1. Factors determining the effect of prophylactic cranial irradiation (PCI) in patients with stage-III nonsmall cell lung cancer: exploratory subgroup analyses of the NVALT-11/DLCRG-02 phase-III study.
    Witlox WJA, Ramaekers BLT, Groen HJM, et al. · Acta Oncol · 2020 · Trial result
    PubMed: PMID 31256737 · NCT00835471 (NVALT10) · Carcinoma, Non-Small-Cell Lung
  2. Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer.
    Sheng J, Fang W, Liu X, et al. · Onco Targets Ther · 2020 · Trial result
    PubMed: PMID 28260924 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
    Leighl NB, Tsao MS, Liu G, et al. · Oncotarget · 2020 · Trial result
    PubMed: PMID 29050231 · NCT01068587 · Carcinoma, Non-Small-Cell Lung
  4. Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.
    Chang N, Duan J, Wang L, et al. · Oncol Lett · 2020 · Trial result
    PubMed: PMID 32782544 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  5. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Borghaei H, Langer CJ, Gadgeel S, et al. · J Thorac Oncol · 2020 · Trial result
    PubMed: PMID 30138764 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  6. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
    Zhong WZ, Chen KN, Chen C, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 31194613 · NCT01407822 (EMERGING) · Carcinoma, Non-Small-Cell Lung
  7. Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study.
    Zhao S, Zhang Z, Fang W, et al. · Front Oncol · 2020 · Derived
    PubMed: PMID 33244458 · NCT01955421 (NSCLC EGFR TKI)
  8. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.
    Yang JC, Gadgeel SM, Sequist LV, et al. · J Thorac Oncol · 2020 · Derived
    PubMed: PMID 30529597 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  9. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
    Xu L, Qi Q, Zhang Y, et al. · Lung Cancer · 2020 · Derived
    PubMed: PMID 31200823 · NCT02031601 (TCL-1) · Carcinoma, Non-Small-Cell Lung
  10. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study.
    Xiong L, Li R, Sun J, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 30158288 · NCT01217619 (ML25444) · Carcinoma, Non-Small-Cell Lung
  11. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
    Westphalen CB, Kukiolka T, Garlipp B, et al. · BMC Cancer · 2020 · Derived
    PubMed: PMID 32093649 · NCT01782690 · Pancreatic Neoplasms
  12. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
    Ramalingam SS, Vansteenkiste J, Planchard D, et al. · N Engl J Med · 2020 · Derived
    PubMed: PMID 31751012 · NCT02296125 (FLAURA)
  13. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D, Boyer MJ, Lee JS, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 30659024 · NCT02296125 (FLAURA)
  14. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K, Garon EB, Seto T, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31591063 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  15. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
    Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 30857956 · NCT02091141 · Neoplasms
  16. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
    Leighl NB, Karaseva N, Nakagawa K, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 31838405 · NCT02296125 (FLAURA)
  17. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
    Kelly RJ, Shepherd FA, Krivoshik A, et al. · Ann Oncol · 2020 · Derived
    PubMed: PMID 31070709 · NCT02588261 (SOLAR) · Carcinoma, Non-Small-Cell Lung
  18. An update on emerging drugs in osteosarcoma: towards tailored therapies?
    Hattinger CM, Patrizio MP, Magagnoli F, et al. · Expert Opin Emerg Drugs · 2020 · Derived
    PubMed: PMID 31401903 · NCT02689336 · Glioma
  19. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR, Foster NR, Kim GP, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 30679315 · NCT00550836 · Pancreatic Neoplasms
  20. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Gray JE, Okamoto I, Sriuranpong V, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 31439584 · NCT02296125 (FLAURA)
  21. Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
    Chalmers AW, Patel S, Boucher K, et al. · Target Oncol · 2020 · Derived
    PubMed: PMID 31346927 · NCT01998126 · Carcinoma, Non-Small-Cell Lung
  22. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers.
    Kim H, Nguyen NP, Turner K, et al. · Nat Genet · 2020 · Background
    PubMed: PMID 32807987 · NCT05827614 (POTENTIATE) · Squamous Cell Carcinoma of Head and Neck

2019 (24 papers)

  1. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
    Gupta N, Goumnerova LC, Manley P, et al. · Neuro Oncol · 2019 · Trial result
    PubMed: PMID 29741745 · NCT01182350 · Diffuse Intrinsic Pontine Glioma
  2. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.
    De Ruysscher D, Dingemans AC, Praag J, et al. · J Clin Oncol · 2019 · Trial result
    PubMed: PMID 29787357 · NCT00835471 (NVALT10) · Carcinoma, Non-Small-Cell Lung
  3. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D, Xu S, Wang Q, et al. · Lancet Respir Med · 2019 · Derived
    PubMed: PMID 30150014 · NCT01683175 · Carcinoma, Non-Small-Cell Lung
  4. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
    Wen F, Zheng H, Zhang P, et al. · BMJ Open · 2019 · Derived
    PubMed: PMID 29654023 · NCT01342965 · Carcinoma, Non-Small-Cell Lung
  5. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
    Strickler JH, Weekes CD, Nemunaitis J, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 30285518 · NCT02099058 · Neoplasms
  6. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ, Kuwada SK, Boucher KM, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 29423501 · NCT01187901 (FAPEST) · Adenomatous Polyposis Coli
  7. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
    Reck M, Garon EB, Paz-Ares L, et al. · Clin Lung Cancer · 2019 · Derived
    PubMed: PMID 29317191 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  8. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.
    Ohe Y, Imamura F, Nogami N, et al. · Jpn J Clin Oncol · 2019 · Derived
    PubMed: PMID 30508196 · NCT02296125 (FLAURA)
  9. Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Morcos PN, Nueesch E, Jaminion F, et al. · Cancer Chemother Pharmacol · 2019 · Derived
    PubMed: PMID 29748847 · NCT01801111 · Carcinoma, Non-Small-Cell Lung
  10. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
    Maurel J, Sánchez-Cabús S, Laquente B, et al. · Cancer Chemother Pharmacol · 2019 · Derived
    PubMed: PMID 30225601 · NCT01389440 (GEMCAD1003)
  11. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
    Markóczy Z, Sárosi V, Kudaba I, et al. · BMC Cancer · 2019 · Derived
    PubMed: PMID 29801465 · NCT01609543
  12. Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
    Labots M, Van der Mijn JC, Dekker H, et al. · Oncologist · 2019 · Derived
    PubMed: PMID 30018133 · NCT01190241 (TSAP) · Neoplasm Metastasis
  13. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.
    Kim HS, Han JY, Shin DH, et al. · Lung Cancer · 2019 · Derived
    PubMed: PMID 30268483 · NCT01482377 · Neoplasms
  14. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy.
    Kapoor S, Srivastava S, Panda D, et al. · Sci Rep · 2019 · Derived
    PubMed: PMID 30120268 · NCT00591383 · Neoplasms
  15. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
    Hainsworth JD, Meric-Bernstam F, Swanton C, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29320312 · NCT02091141 · Neoplasms
  16. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    Haas M, Siveke JT, Schenk M, et al. · Eur J Cancer · 2019 · Derived
    PubMed: PMID 29549862 · NCT01729481 (ML22774)
  17. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
    Gridelli C, de Castro Carpeno J, Dingemans AC, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 30177994 · NCT01351415
  18. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
    Goss GD, Felip E, Cobo M, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 29902295 · NCT01523587 · Carcinoma, Non-Small-Cell Lung
  19. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
    Gold KA, Kies MS, William WN, et al. · Cancer · 2019 · Derived
    PubMed: PMID 29579331 · NCT01198028
  20. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Gadgeel SM, Stevenson JP, Langer CJ, et al. · Lung Cancer · 2019 · Derived
    PubMed: PMID 30429032 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  21. Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.
    Bauman JE, Duvvuri U, Gooding WE, et al. · JCI Insight · 2019 · Derived
    PubMed: PMID 28352657 · NCT00779389 · Carcinoma, Non-Small-Cell Lung
  22. Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer.
    Abravan A, Eide HA, Løndalen AM, et al. · Mol Imaging Biol · 2019 · Derived
    PubMed: PMID 29916117 · NCT02714530 (ThoRaT) · Neoplasms
  23. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
    Abdel-Wahab R, Varadhachary GR, Bhosale PR, et al. · J Hematol Oncol · 2019 · Derived
    PubMed: PMID 29843755 · NCT00769483 · Pancreatic Neoplasms
  24. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
    Italiano A, Infante JR, Shapiro GI, et al. · Ann Oncol · 2019 · Background
    PubMed: PMID 29788155 · NCT05827614 (POTENTIATE) · Squamous Cell Carcinoma of Head and Neck

2018 (10 papers)

  1. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
    Gautschi O, Rothschild SI, Li Q, et al. · Clin Lung Cancer · 2018 · Trial result
    PubMed: PMID 27993482 · NCT01116219 · Carcinoma, Non-Small-Cell Lung
  2. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Spigel DR, Rubin MS, Gian VG, et al. · Lung Cancer · 2018 · Derived
    PubMed: PMID 29110854 · NCT00609804 · Carcinoma, Non-Small-Cell Lung
  3. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC, Ohe Y, Vansteenkiste J, et al. · N Engl J Med · 2018 · Derived
    PubMed: PMID 29151359 · NCT02296125 (FLAURA)
  4. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
    Sample DC, Samadder NJ, Pappas LM, et al. · BMC Gastroenterol · 2018 · Derived
    PubMed: PMID 30012100 · NCT01187901 (FAPEST) · Adenomatous Polyposis Coli
  5. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R, Dafni U, Felip E, et al. · Lancet Respir Med · 2018 · Derived
    PubMed: PMID 28408243 · NCT01562028 (BELIEF) · Carcinoma, Non-Small-Cell Lung
  6. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM, Infante JR, Kim KB, et al. · BMC Cancer · 2018 · Derived
    PubMed: PMID 28264648 · NCT00600496 · Lung Neoplasms
  7. A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
    Infante JR, Cohen RB, Kim KB, et al. · Invest New Drugs · 2018 · Derived
    PubMed: PMID 28424891 · NCT00600496 · Lung Neoplasms
  8. Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
    Gadgeel S, Goss G, Soria JC, et al. · Lung Cancer · 2018 · Derived
    PubMed: PMID 28577938 · NCT01523587 · Carcinoma, Non-Small-Cell Lung
  9. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.
    Cascone T, Gold KA, Swisher SG, et al. · Ann Thorac Surg · 2018 · Derived
    PubMed: PMID 29217088 · NCT00254384 · Carcinoma, Non-Small-Cell Lung
  10. Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
    Matsuoka H, Kaneda H, Sakai K, et al. · Clin Lung Cancer · 2018 · Background
    PubMed: PMID 28341110 · NCT03123484 · Carcinoma, Non-Small-Cell Lung

2017 (16 papers)

  1. Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.
    Redig AJ, Costa DB, Taibi M, et al. · JAMA Oncol · 2017 · Trial result
    PubMed: PMID 27387964 · NCT00997334 · Carcinoma, Non-Small-Cell Lung
  2. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ, Gadgeel SM, Borghaei H, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27745820 · NCT02039674 · Carcinoma, Non-Small-Cell Lung
  3. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
    Belin L, Kamal M, Mauborgne C, et al. · Ann Oncol · 2017 · Trial result
    PubMed: PMID 27993804 · NCT01771458 (SHIVA) · Neoplasm Metastasis
  4. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.
    Baty F, Joerger M, Früh M, et al. · J Transl Med · 2017 · Trial result
    PubMed: PMID 28359318 · NCT00354549 · Carcinoma, Non-Small-Cell Lung
  5. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
    Zhou Q, Yang JJ, Chen ZH, et al. · J Hematol Oncol · 2017 · Derived
    PubMed: PMID 27619632 · NCT01024413 · Lung Neoplasms
  6. Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.
    Sutiman N, Zhang Z, Tan EH, et al. · PLoS One · 2017 · Derived
    PubMed: PMID 27135612 · NCT00702182 · Carcinoma, Non-Small-Cell Lung
  7. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Neal JW, Dahlberg SE, Wakelee HA, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27825638 · NCT01708954 · Carcinoma, Non-Small-Cell Lung
  8. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
    Irigoyen A, Gallego J, Guillén Ponce C, et al. · Eur J Cancer · 2017 · Derived
    PubMed: PMID 28222309 · NCT01303029 (GECA) · Pancreatic Neoplasms
  9. Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
    Garon EB, Reck M, Paz-Ares L, et al. · Clin Lung Cancer · 2017 · Derived
    PubMed: PMID 27894601 · NCT02411448 (RELAY) · Carcinoma, Non-Small-Cell Lung
  10. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
    Gandara DR, Leighl N, Delord JP, et al. · J Thorac Oncol · 2017 · Derived
    PubMed: PMID 27876675 · NCT01192165 · Neoplasms
  11. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
    Gadgeel SM, Shaw AT, Govindan R, et al. · J Clin Oncol · 2017 · Derived
    PubMed: PMID 27863201 · NCT01801111 · Carcinoma, Non-Small-Cell Lung
  12. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity.
    Turner KM, Deshpande V, Beyter D, et al. · Nature · 2017 · Background
    PubMed: PMID 28178237 · NCT05827614 (POTENTIATE) · Squamous Cell Carcinoma of Head and Neck
  13. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA, Hellmann MD, Brahmer JR, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27354481 · NCT01454102 · Carcinoma, Non-Small-Cell Lung
  14. EGFR inhibition in NSCLC: New findings…. and opened questions?
    Passiglia F, Listì A, Castiglia M, et al. · Crit Rev Oncol Hematol · 2017 · Background
    PubMed: PMID 28325254 · NCT03123484 · Carcinoma, Non-Small-Cell Lung
  15. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
    Hellmann MD, Rizvi NA, Goldman JW, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27932067 · NCT01454102 · Carcinoma, Non-Small-Cell Lung
  16. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Gettinger S, Rizvi NA, Chow LQ, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27354485 · NCT01454102 · Carcinoma, Non-Small-Cell Lung

2016 (43 papers)

  1. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q, Liu XY, Zhang T, et al. · Hum Immunol · 2016 · Trial result
    PubMed: PMID 25305457 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.
    Weiss JM, Villaruz LC, O'Brien J, et al. · Clin Lung Cancer · 2016 · Trial result
    PubMed: PMID 26774201 · NCT01344824 · Carcinoma, Non-Small-Cell Lung
  3. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Tolcher AW, LoRusso P, Arzt J, et al. · Cancer Chemother Pharmacol · 2016 · Trial result
    PubMed: PMID 26420235 · NCT01009073
  4. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
    Semrad T, Barzi A, Lenz HJ, et al. · Int J Clin Oncol · 2016 · Trial result
    PubMed: PMID 25091263 · NCT00810719 · Pancreatic Neoplasms
  5. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
    Melosky B, Anderson H, Burkes RL, et al. · J Clin Oncol · 2016 · Trial result
    PubMed: PMID 26573073 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  6. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.
    Goss GD, Jonker DJ, Laurie SA, et al. · J Transl Med · 2016 · Trial result
    PubMed: PMID 27036206 · NCT00966472 · Carcinoma, Non-Small-Cell Lung
  7. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
    Franzini A, Baty F, Macovei II, et al. · Clin Cancer Res · 2016 · Trial result
    PubMed: PMID 25922429 · NCT00354549 · Carcinoma, Non-Small-Cell Lung
  8. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
    Zhou C, Wu YL, Chen G, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26141208 · NCT00874419 (ML20981) · Carcinoma, Non-Small-Cell Lung
  9. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.
    Zhong W, Yang X, Yan H, et al. · J Hematol Oncol · 2016 · Derived
    PubMed: PMID 25981169 · NCT00600587 · Carcinoma, Non-Small-Cell Lung
  10. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H, Azuma K, Yamamoto N, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26153496 · NCT01377376 (ATTENTION) · Carcinoma, Non-Small-Cell Lung
  11. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
    Wu YL, Zhou C, Liam CK, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26105600 · NCT01342965 · Carcinoma, Non-Small-Cell Lung
  12. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
    William WN, Papadimitrakopoulou V, Lee JJ, et al. · JAMA Oncol · 2016 · Derived
    PubMed: PMID 26540028 · NCT00402779 · Mouth Neoplasms
  13. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
    Wang JP, Wu CY, Yeh YC, et al. · Oncotarget · 2016 · Derived
    PubMed: PMID 26046796 · NCT01608841 · Pancreatic Neoplasms
  14. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM, Lui VW, Egloff AM, et al. · JAMA Oncol · 2016 · Derived
    PubMed: PMID 26181029 · NCT00779389 · Carcinoma, Non-Small-Cell Lung
  15. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C, Chibaudel B, Samson B, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26474518 · NCT00265824 (DREAM) · Colorectal Neoplasms
  16. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
    Thomas M, Fischer J, Andreas S, et al. · Eur Respir J · 2016 · Derived
    PubMed: PMID 25792638 · NCT00536640 (INNOVATIONS) · Carcinoma, Non-Small-Cell Lung
  17. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A, Chen Y, Steinberg SM, et al. · Oncotarget · 2016 · Derived
    PubMed: PMID 26028668 · NCT01306045 · Carcinoma, Non-Small-Cell Lung
  18. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Takeda M, Yamanaka T, Seto T, et al. · Cancer · 2016 · Derived
    PubMed: PMID 26828788 · NCT01351415
  19. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3.
    Shultz DB, Pai J, Chiu W, et al. · PLoS One · 2016 · Derived
    PubMed: PMID 26808546 · NCT00040183 · Pancreatic Neoplasms
  20. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.
    Scagliotti GV, Bondarenko I, Blackhall F, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25395283 · NCT00673049 (NSCLC) · Carcinoma, Non-Small-Cell Lung
  21. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
    Samadder NJ, Neklason DW, Boucher KM, et al. · JAMA · 2016 · Derived
    PubMed: PMID 27002448 · NCT01187901 (FAPEST) · Adenomatous Polyposis Coli
  22. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
    Rulli E, Marabese M, Torri V, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26209642 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  23. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
    Ramalingam SS, O'Byrne K, Boyer M, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26768165 · NCT00769067 · Carcinoma, Non-Small-Cell Lung
  24. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
    Platt A, Morten J, Ji Q, et al. · BMC Cancer · 2016 · Derived
    PubMed: PMID 25881079 · NCT00364351 · Carcinoma, Non-Small-Cell Lung
  25. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.
    Park K, Yu CJ, Kim SW, et al. · JAMA Oncol · 2016 · Derived
    PubMed: PMID 26720423 · NCT01310036
  26. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
    Middleton G, Crack LR, Popat S, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26410619 · NCT02154490
  27. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
    Massarelli E, Lin H, Ginsberg LE, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26025965 · NCT00942734 · Head and Neck Neoplasms
  28. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
    Marabese M, Ganzinelli M, Garassino MC, et al. · Oncotarget · 2016 · Derived
    PubMed: PMID 26416458 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  29. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lim SM, Cho BC, Kim SW, et al. · Lung Cancer · 2016 · Derived
    PubMed: PMID 26898607 · NCT00801385 · Carcinoma, Non-Small-Cell Lung
  30. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH, Leung DK, Choy TS, et al. · BMC Cancer · 2016 · Derived
    PubMed: PMID 26911310 · NCT02625168 · Carcinoma, Non-Small-Cell Lung
  31. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C, Delord JP, Gonçalves A, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26342236 · NCT01771458 (SHIVA) · Neoplasm Metastasis
  32. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.
    Kim ST, Jang KT, Lee SJ, et al. · BMC Cancer · 2016 · Derived
    PubMed: PMID 26189560 · NCT01149122
  33. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
    Kelly K, Altorki NK, Eberhardt WE, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 26324372 · NCT00373425 (RADIANT) · Carcinoma, Non-Small-Cell Lung
  34. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.
    Kaseb AO, Morris JS, Iwasaki M, et al. · Onco Targets Ther · 2016 · Derived
    PubMed: PMID 26929648 · NCT01180959 · Carcinoma, Hepatocellular
  35. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N, Mayo-de las Casas C, Queralt C, et al. · JAMA Oncol · 2016 · Derived
    PubMed: PMID 26181014 · NCT00446225 (EURTAC) · Carcinoma, Non-Small-Cell Lung
  36. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
    Hammel P, Huguet F, van Laethem JL, et al. · JAMA · 2016 · Derived
    PubMed: PMID 27139057 · NCT00634725 · Pancreatic Neoplasms
  37. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
    Hagman H, Frödin JE, Berglund Å, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26483047 · NCT01229813 (ACT2) · Colorectal Neoplasms
  38. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
    Goldman JW, Shi P, Reck M, et al. · Clin Lung Cancer · 2016 · Derived
    PubMed: PMID 26432508 · NCT02152631 (JUNIPER) · Carcinoma, Non-Small-Cell Lung
  39. Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).
    De Grève J, Van Meerbeeck J, Vansteenkiste JF, et al. · PLoS One · 2016 · Derived
    PubMed: PMID 27032107 · NCT00339586 · Carcinoma, Non-Small-Cell Lung
  40. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
    Carter CA, Rajan A, Keen C, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26802155 · NCT01229150 · Carcinoma, Non-Small-Cell Lung
  41. Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.
    Cadranel J, Gervais R, Merle P, et al. · Eur Respir J · 2016 · Derived
    PubMed: PMID 26381515 · NCT00384826 · Adenocarcinoma, Bronchiolo-Alveolar
  42. A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response.
    Berry SM, Petzold EA, Dull P, et al. · Clin Trials · 2016 · Derived
    PubMed: PMID 26768569 · NCT02380625 · Hemorrhagic Fever, Ebola
  43. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND, Heidari P, Kunawudhi A, et al. · Technol Cancer Res Treat · 2016 · Background
    PubMed: PMID 25759424 · NCT00977470 · Carcinoma, Non-Small-Cell Lung

2015 (34 papers)

  1. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, et al. · Lancet Oncol · 2015 · Trial result
    PubMed: PMID 25175099 · NCT02759614
  2. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
    Saba NF, Hurwitz SJ, Kono SA, et al. · Cancer Prev Res (Phila) · 2015 · Trial result
    PubMed: PMID 24085777 · NCT00314262 · Precancerous Conditions
  3. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH, Lee JH, Lim YS, et al. · Gastroenterology · 2015 · Trial result
    PubMed: PMID 25747273 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M, Baty F, Früh M, et al. · Lung Cancer · 2015 · Trial result
    PubMed: PMID 24928469 · NCT00354549 · Carcinoma, Non-Small-Cell Lung
  5. NK cell phenotypic modulation in lung cancer environment.
    Jin S, Deng Y, Hao JW, et al. · PLoS One · 2015 · Trial result
    PubMed: PMID 25299645 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  6. Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
    Auliac JB, Chouaid C, Greillier L, et al. · Lung Cancer · 2015 · Trial result
    PubMed: PMID 25082565 · NCT01350817 (TARSEQ) · Carcinoma, Non-Small-Cell Lung
  7. Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
    Zhao HY, Chen GY, Huang Y, et al. · Medicine (Baltimore) · 2015 · Derived
    PubMed: PMID 25590835 · NCT00816868 · Carcinoma, Non-Small-Cell Lung
  8. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
    Wheler JJ, Moulder SL, Naing A, et al. · Oncotarget · 2015 · Derived
    PubMed: PMID 24912489 · NCT01197170 · Neoplasm Metastasis
  9. Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.
    Warner E, Liebes L, Levinson B, et al. · Oncologist · 2015 · Derived
    PubMed: PMID 24563078 · NCT01003938 · Ovarian Neoplasms
  10. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
    Suleiman AA, Frechen S, Scheffler M, et al. · J Thorac Oncol · 2015 · Derived
    PubMed: PMID 25226426 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  11. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
    Soria JC, LoRusso P, Bahleda R, et al. · Oncologist · 2015 · Derived
    PubMed: PMID 25669662 · NCT00692640 · Carcinoma, Non-Small-Cell Lung
  12. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC, Felip E, Cobo M, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 26156651 · NCT01523587 · Carcinoma, Non-Small-Cell Lung
  13. Challenges in predicting which oral mucosal potentially malignant disease will progress to neoplasia.
    Scully C · Oral Dis · 2015 · Derived
    PubMed: PMID 24320967 · NCT00402779 · Mouth Neoplasms
  14. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    Scagliotti G, von Pawel J, Novello S, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 26169611 · NCT01244191 · Carcinoma, Non-Small-Cell Lung
  15. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
    Ramalingam SS, Jänne PA, Mok T, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 25439691 · NCT01360554 (ARCHER 1009) · Carcinoma, Non-Small-Cell Lung
  16. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck.
    Psyrri A, Rampias T, Vermorken JB, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 25057165 · NCT00410826 · Squamous Cell Carcinoma of Head and Neck
  17. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.
    Propper D, Davidenko I, Bridgewater J, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 24827134 · NCT00674973 · Pancreatic Neoplasms
  18. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
    Ormanns S, Siveke JT, Heinemann V, et al. · BMC Cancer · 2015 · Derived
    PubMed: PMID 25164437 · NCT00440167 · Pancreatic Neoplasms
  19. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Mok TS, Geater SL, Iannotti N, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 24827127 · NCT01104155 · Carcinoma, Non-Small-Cell Lung
  20. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
    Lopez-Chavez A, Thomas A, Rajan A, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25667274 · NCT01306045 · Carcinoma, Non-Small-Cell Lung
  21. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
    Kordes S, Pollak MN, Zwinderman AH, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 26067687 · NCT01210911 (GEM) · Pancreatic Neoplasms
  22. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R, Allen PK, Wei X, et al. · Int J Radiat Oncol Biol Phys · 2015 · Derived
    PubMed: PMID 25968826 · NCT00563784 · Carcinoma, Non-Small-Cell Lung
  23. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
    Koeppen H, Yu W, Zha J, et al. · Clin Cancer Res · 2015 · Derived
    PubMed: PMID 24687921 · NCT01456325
  24. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.
    Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, et al. · Transl Lung Cancer Res · 2015 · Derived
    PubMed: PMID 25806291 · NCT00446225 (EURTAC) · Carcinoma, Non-Small-Cell Lung
  25. An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
    Jotte RM, Von Hoff DD, Braiteh F, et al. · Invest New Drugs · 2015 · Derived
    PubMed: PMID 25260842 · NCT01284335 · Neoplasm Metastasis
  26. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Johnson ML, Yu HA, Hart EM, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25870087 · NCT01259089 · Carcinoma, Non-Small-Cell Lung
  27. Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
    Huang Y, Zhang L, Shi Y, et al. · Jpn J Clin Oncol · 2015 · Derived
    PubMed: PMID 25855621 · NCT00949910 · Carcinoma, Non-Small-Cell Lung
  28. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
    Gross ND, Bauman JE, Gooding WE, et al. · Clin Cancer Res · 2015 · Derived
    PubMed: PMID 24727329 · NCT00779389 · Carcinoma, Non-Small-Cell Lung
  29. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.
    Gold KA, Lee JJ, Harun N, et al. · Oncologist · 2015 · Derived
    PubMed: PMID 25170013 · NCT00826449 · Carcinoma, Non-Small-Cell Lung
  30. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
    Gitlitz BJ, Bernstein E, Santos ES, et al. · J Thorac Oncol · 2015 · Derived
    PubMed: PMID 24736085 · NCT00652340 (TP2001-201) · Carcinoma, Non-Small-Cell Lung
  31. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
    Di Maio M, Gallo C, Leighl NB, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25624439 · NCT00349219 (TORCH)
  32. Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases.
    Hendriks LE, Troost EG, Steward A, et al. · Acta Oncol · 2015 · Background
    PubMed: PMID 24754845 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  33. Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both.
    El Gantery MM, Abd El Baky HM, El Hossieny HA, et al. · Radiat Oncol · 2015 · Background
    PubMed: PMID 24884624 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  34. AXL mediates resistance to cetuximab therapy.
    Brand TM, Iida M, Stein AP, et al. · Cancer Res · 2015 · Background
    PubMed: PMID 25136066 · NCT02424617 · Carcinoma, Non-Small-Cell Lung

2014 (35 papers)

  1. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
    Wen PY, Chang SM, Lamborn KR, et al. · Neuro Oncol · 2014 · Trial result
    PubMed: PMID 24470557 · NCT00112736 · Brain Neoplasms
  2. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
    Stephenson JJ, Nemunaitis J, Joy AA, et al. · Lung Cancer · 2014 · Trial result
    PubMed: PMID 24388167 · NCT00732810 · Carcinoma, Non-Small-Cell Lung
  3. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
    Shi SB, Tang XY, Tian J, et al. · J Immunother · 2014 · Trial result
    PubMed: PMID 24714359 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
    Sequist LV, Yang JC, Yamamoto N, et al. · J Clin Oncol · 2014 · Trial result
    PubMed: PMID 23816960 · NCT02759614
  5. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N, Rosell R, Cardenal F, et al. · Lung Cancer · 2014 · Trial result
    PubMed: PMID 24636848 · NCT00503971 · Carcinoma, Non-Small-Cell Lung
  6. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial.
    Moran T, Felip E, Keedy V, et al. · Exp Hematol Oncol · 2014 · Trial result
    PubMed: PMID 25414803 · NCT00654420 · Carcinoma, Non-Small-Cell Lung
  7. Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
    Mita MM, Joy AA, Mita A, et al. · Clin Breast Cancer · 2014 · Trial result
    PubMed: PMID 24393852 · NCT00732810 · Carcinoma, Non-Small-Cell Lung
  8. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
    He S, Yin T, Li D, et al. · J Transl Med · 2014 · Trial result
    PubMed: PMID 23937717 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  9. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
    Vergote IB, Jimeno A, Joly F, et al. · J Clin Oncol · 2014 · Derived
    PubMed: PMID 24366937 · NCT00263822 · Carcinoma, Ovarian Epithelial
  10. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
    Renouf DJ, Tang PA, Hedley D, et al. · Eur J Cancer · 2014 · Derived
    PubMed: PMID 24857345 · NCT00497224 · Pancreatic Neoplasms
  11. Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
    Petty WJ, Laudadio J, Brautnick L, et al. · Int J Oncol · 2014 · Derived
    PubMed: PMID 24100924 · NCT01557959 · Carcinoma, Non-Small-Cell Lung
  12. Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
    Molife LR, Yan L, Vitfell-Rasmussen J, et al. · J Hematol Oncol · 2014 · Derived
    PubMed: PMID 24387695 · NCT00848718 · Neoplasms
  13. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.
    Mita M, Gordon M, Rosen L, et al. · Cancer Chemother Pharmacol · 2014 · Derived
    PubMed: PMID 24849582 · NCT00881166 (SGI-0470-02)
  14. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N, Ou W, Yang H, et al. · Cancer · 2014 · Derived
    PubMed: PMID 24481719 · NCT01565538 · Carcinoma, Non-Small-Cell Lung
  15. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
    Lee DH, Lee JS, Kim SW, et al. · Eur J Cancer · 2014 · Derived
    PubMed: PMID 23890768 · NCT00550173 · Carcinoma, Non-Small-Cell Lung
  16. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Kurzrock R, Atkins J, Wheler J, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 23676418 · NCT00495872
  17. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.
    Johnsson A, Hagman H, Frödin JE, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 23788755 · NCT00598156 (ACT) · Colorectal Neoplasms
  18. Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
    Hughes B, Mileshkin L, Townley P, et al. · Oncologist · 2014 · Derived
    PubMed: PMID 24457379 · NCT00855894 (PENGUIN) · Carcinoma, Non-Small-Cell Lung
  19. A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
    Hollebecque A, Houédé N, Cohen EE, et al. · Eur J Cancer · 2014 · Derived
    PubMed: PMID 24456794 · NCT01115803 · Carcinoma, Non-Small-Cell Lung
  20. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
    Groen HJ, Socinski MA, Grossi F, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 23788751 · NCT00265317 (SUN1058) · Carcinoma, Non-Small-Cell Lung
  21. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
    Gregorc V, Novello S, Lazzari C, et al. · Lancet Oncol · 2014 · Derived
    PubMed: PMID 24831979 · NCT00989690 · Carcinoma, Non-Small-Cell Lung
  22. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
    Falchook GS, Moulder SL, Wheler JJ, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 24158411 · NCT00543504
  23. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
    Costa C, Molina MA, Drozdowskyj A, et al. · Clin Cancer Res · 2014 · Derived
    PubMed: PMID 24493829 · NCT00446225 (EURTAC) · Carcinoma, Non-Small-Cell Lung
  24. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T, Tsai CM, Tsao CJ, et al. · Lung Cancer · 2014 · Derived
    PubMed: PMID 23992877 · NCT00531960 · Carcinoma, Non-Small-Cell Lung
  25. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
    Casal Rubio J, Fírvida-Pérez JL, Lázaro-Quintela M, et al. · Cancer Chemother Pharmacol · 2014 · Derived
    PubMed: PMID 24352251 · NCT00466284 · Carcinoma, Non-Small-Cell Lung
  26. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
    Brahmer JR, Lee JW, Traynor AM, et al. · Eur J Cancer · 2014 · Derived
    PubMed: PMID 24246704 · NCT00085280 · Carcinoma, Non-Small-Cell Lung
  27. Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.
    Blaszkowsky LS, Ryan DP, Szymonifka J, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 24356623 · NCT00307736 · Rectal Neoplasms
  28. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
    Belani CP, Nemunaitis JJ, Chachoua A, et al. · Cancer Biol Ther · 2014 · Derived
    PubMed: PMID 23792641 · NCT00321815 · Carcinoma, Non-Small-Cell Lung
  29. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
    Bauman JE, Austin MC, Schmidt R, et al. · Br J Cancer · 2014 · Derived
    PubMed: PMID 24064970 · NCT00410826 · Squamous Cell Carcinoma of Head and Neck
  30. A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
    Aerts JG, Codrington H, Lankheet NA, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 23986090 · NCT00835471 (NVALT10) · Carcinoma, Non-Small-Cell Lung
  31. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
    Zhuang H, Yuan Z, Wang J, et al. · Drug Des Devel Ther · 2014 · Background
    PubMed: PMID 24133369 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  32. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study.
    Yamamoto M, Serizawa T, Shuto T, et al. · Lancet Oncol · 2014 · Background
    PubMed: PMID 24621620 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  33. Instructions for producing a mouse model of glucocorticoid-induced osteoporosis.
    Thiele S, Baschant U, Rauch A, et al. · Bonekey Rep · 2014 · Background
    PubMed: PMID 25120909 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  34. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
    Ishikawa M, Sonobe M, Nakayama E, et al. · Ann Surg Oncol · 2014 · Background
    PubMed: PMID 23242819 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  35. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
    Dy GK, Infante JR, Eckhardt SG, et al. · Invest New Drugs · 2014 · Background
    PubMed: PMID 23135778 · NCT00619424 · Carcinoma, Non-Small-Cell Lung

2013 (37 papers)

  1. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F, Droege C, Betticher D, et al. · Lung Cancer · 2013 · Trial result
    PubMed: PMID 23009726 · NCT00354549 · Carcinoma, Non-Small-Cell Lung
  2. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
    Wu YL, Lee JS, Thongprasert S, et al. · Lancet Oncol · 2013 · Trial result
    PubMed: PMID 23782814 · NCT02098954 · Carcinoma, Non-Small-Cell Lung
  3. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.
    Ware KE, Hinz TK, Kleczko E, et al. · Oncogenesis · 2013 · Trial result
    PubMed: PMID 23552882 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.
    Suda K, Mizuuchi H, Maehara Y, et al. · Cancer Metastasis Rev · 2013 · Trial result
    PubMed: PMID 22736441 · NCT02098954 · Carcinoma, Non-Small-Cell Lung
  5. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
    Socinski MA, Stinchcombe TE, Moore DT, et al. · J Clin Oncol · 2013 · Trial result
    PubMed: PMID 23045594 · NCT00280150 · Carcinoma, Non-Small-Cell Lung
  6. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
    Riggs H, Jalal SI, Baghdadi TA, et al. · Clin Lung Cancer · 2013 · Trial result
    PubMed: PMID 23102811 · NCT00367601 · Lung Neoplasms
  7. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
    Peereboom DM, Ahluwalia MS, Ye X, et al. · Neuro Oncol · 2013 · Trial result
    PubMed: PMID 23328813 · NCT00445588 · Brain Neoplasms
  8. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.
    Layman RM, Ruppert AS, Lynn M, et al. · Cancer Chemother Pharmacol · 2013 · Trial result
    PubMed: PMID 23430121 · NCT00834678 · Breast Neoplasms
  9. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.
    Horowitz NS, Olawaiye AB, Borger DR, et al. · Gynecol Oncol · 2013 · Trial result
    PubMed: PMID 22750258 · NCT00476476 · Carcinoma, Squamous Cell
  10. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM, Fan KY, Wild AT, et al. · Int J Radiat Oncol Biol Phys · 2013 · Trial result
    PubMed: PMID 23773391 · NCT00313560 · Pancreatic Neoplasms
  11. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
    Heath CH, Deep NL, Nabell L, et al. · Int J Radiat Oncol Biol Phys · 2013 · Trial result
    PubMed: PMID 23182701 · NCT00369512 (RAD0503) · Neoplasms
  12. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
    Goldberg SB, Supko JG, Neal JW, et al. · J Thorac Oncol · 2013 · Trial result
    PubMed: PMID 22878749 · NCT01026844 · Carcinoma, Non-Small-Cell Lung
  13. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Francois E, Bennouna J, Chamorey E, et al. · Chemotherapy · 2013 · Trial result
    PubMed: PMID 23235319 · NCT00885066 · Pancreatic Neoplasms
  14. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
    Di Maio M, Leighl NB, Gallo C, et al. · J Thorac Oncol · 2013 · Trial result
    PubMed: PMID 23154555 · NCT00349219 (TORCH)
  15. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Bauman JE, Arias-Pulido H, Lee SJ, et al. · Oral Oncol · 2013 · Trial result
    PubMed: PMID 23384718 · NCT01009203 · Carcinoma, Squamous Cell
  16. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
    Welsh JW, Komaki R, Amini A, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23341526 · NCT00871923 · Carcinoma, Non-Small-Cell Lung
  17. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.
    Tam AL, Kim ES, Lee JJ, et al. · J Thorac Oncol · 2013 · Derived
    PubMed: PMID 23442309 · NCT00411632 · Carcinoma, Non-Small-Cell Lung
  18. Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
    Scheffler M, Zander T, Nogova L, et al. · PLoS One · 2013 · Derived
    PubMed: PMID 23308140 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  19. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
    Scagliotti GV, Novello S, Schiller JH, et al. · Clin Lung Cancer · 2013 · Derived
    PubMed: PMID 22440336 · NCT01244191 · Carcinoma, Non-Small-Cell Lung
  20. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
    Patel SP, Lazar AJ, Papadopoulos NE, et al. · Cancer · 2013 · Derived
    PubMed: PMID 22972589 · NCT00600496 · Lung Neoplasms
  21. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
    Martins RG, Parvathaneni U, Bauman JE, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23460709 · NCT00410826 · Squamous Cell Carcinoma of Head and Neck
  22. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE, Kabbinavar F, Fehrenbacher L, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 24101054 · NCT00257608 · Carcinoma, Non-Small-Cell Lung
  23. A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer.
    Hwang IG, Jang JS, Oh SY, et al. · Invest New Drugs · 2013 · Derived
    PubMed: PMID 22302349 · NCT00922896 · Pancreatic Neoplasms
  24. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
    Heinemann V, Vehling-Kaiser U, Waldschmidt D, et al. · Gut · 2013 · Derived
    PubMed: PMID 22773551 · NCT00440167 · Pancreatic Neoplasms
  25. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
    Hansen TF, Christensen Rd, Andersen RF, et al. · Br J Cancer · 2013 · Derived
    PubMed: PMID 23922111 · NCT00598156 (ACT) · Colorectal Neoplasms
  26. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD, Rubin MS, Spigel DR, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23032625 · NCT00737243 · Carcinoma
  27. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
    Govindarajan R, Siegel E, Makhoul I, et al. · Am J Clin Oncol · 2013 · Derived
    PubMed: PMID 22643560 · NCT00287222 · Carcinoma, Hepatocellular
  28. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC, Martelli O, Broggini M, et al. · Lancet Oncol · 2013 · Derived
    PubMed: PMID 23883922 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  29. A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
    Akerley W, Boucher K, Rich N, et al. · Lung Cancer · 2013 · Derived
    PubMed: PMID 23273522 · NCT00585377 · Neoplasms
  30. [Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer].
    Xu XW, Yuan ZZ, Hu WH, et al. · Zhongguo Zhong Yao Za Zhi · 2013 · Background
    PubMed: PMID 23944083 · NCT03123484 · Carcinoma, Non-Small-Cell Lung
  31. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
    Wu YL, Zhou C, Cheng Y, et al. · Ann Oncol · 2013 · Background
    PubMed: PMID 23129122 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  32. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
    Shin DM, Zhang H, Saba NF, et al. · Clin Cancer Res · 2013 · Background
    PubMed: PMID 23422093 · NCT00314262 · Precancerous Conditions
  33. Survival and intracranial control of patients with 5 or more brain metastases treated with gamma knife stereotactic radiosurgery.
    Raldow AC, Chiang VL, Knisely JP, et al. · Am J Clin Oncol · 2013 · Background
    PubMed: PMID 22706180 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  34. Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs.
    Li QQ, Wang G, Huang F, et al. · Med Oncol · 2013 · Background
    PubMed: PMID 23397083 · NCT03123484 · Carcinoma, Non-Small-Cell Lung
  35. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
    Byers LA, Diao L, Wang J, et al. · Clin Cancer Res · 2013 · Background
    PubMed: PMID 23091115 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  36. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.
    Bendell JC, Meluch A, Peyton J, et al. · Clin Adv Hematol Oncol · 2013 · Background
    PubMed: PMID 22895283 · NCT00393068 · Esophageal Neoplasms
  37. Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
    Augustin A, Lamerz J, Meistermann H, et al. · Mol Cancer Ther · 2013 · Background
    PubMed: PMID 23371860 · NCT06161558 · Neoplasms

2012 (30 papers)

  1. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
    You B, Le Tourneau C, Chen EX, et al. · Am J Clin Oncol · 2012 · Trial result
    PubMed: PMID 21358293 · NCT00603915 · Nasopharyngeal Neoplasms
  2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R, Carcereny E, Gervais R, et al. · Lancet Oncol · 2012 · Trial result
    PubMed: PMID 22285168 · NCT00446225 (EURTAC) · Carcinoma, Non-Small-Cell Lung
  3. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
    Pérol M, Chouaid C, Pérol D, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22949150 · NCT00300586 · Carcinoma, Non-Small-Cell Lung
  4. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
    Parkhurst MR, Riley JP, Dudley ME, et al. · Clin Cancer Res · 2012 · Trial result
    PubMed: PMID 21844012 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  5. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
    Gridelli C, Ciardiello F, Gallo C, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22778317 · NCT00349219 (TORCH)
  6. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG, Ramasubbaiah R, Yu M, et al. · Oncologist · 2012 · Trial result
    PubMed: PMID 22210086 · NCT00532441 · Carcinoma, Hepatocellular
  7. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.
    Beijers AJ, Jongen JL, Vreugdenhil G, et al. · Neth J Med · 2012 · Trial result
    PubMed: PMID 22271810 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  8. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer.
    Yoo DS, Kirkpatrick JP, Craciunescu O, et al. · Clin Cancer Res · 2012 · Derived
    PubMed: PMID 22253412 · NCT00140556 · Head and Neck Neoplasms
  9. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
    Ramalingam SS, Spigel DR, Chen D, et al. · J Clin Oncol · 2012 · Derived
    PubMed: PMID 22025157 · NCT00760929
  10. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.
    Philip PA, Mahoney MR, Holen KD, et al. · Cancer · 2012 · Derived
    PubMed: PMID 21953248 · NCT00365391 · Carcinoma, Hepatocellular
  11. A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
    Padda SK, Krupitskaya Y, Chhatwani L, et al. · Cancer Chemother Pharmacol · 2012 · Derived
    PubMed: PMID 22160298 · NCT00452413 · Carcinoma, Non-Small-Cell Lung
  12. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
    Monti DA, Mitchell E, Bazzan AJ, et al. · PLoS One · 2012 · Derived
    PubMed: PMID 22272248 · NCT00954525 · Pancreatic Neoplasms
  13. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J, Park SH, Chang HM, et al. · Lancet Oncol · 2012 · Derived
    PubMed: PMID 22192731 · NCT01149122
  14. The BATTLE trial: personalizing therapy for lung cancer.
    Kim ES, Herbst RS, Wistuba II, et al. · Cancer Discov · 2012 · Derived
    PubMed: PMID 22586319 · NCT00410059 · Carcinoma, Non-Small-Cell Lung
  15. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
    Heigener DF, Wu YL, van Zandwijk N, et al. · Lung Cancer · 2012 · Derived
    PubMed: PMID 21439671 · NCT00949910 · Carcinoma, Non-Small-Cell Lung
  16. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C, Bennouna J, de Castro J, et al. · Clin Lung Cancer · 2012 · Derived
    PubMed: PMID 21705281 · NCT01351415
  17. Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters.
    Craciunescu OI, Yoo DS, Cleland E, et al. · Int J Radiat Oncol Biol Phys · 2012 · Derived
    PubMed: PMID 21985945 · NCT00140556 · Head and Neck Neoplasms
  18. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T, Stelmakh L, Cicenas S, et al. · Lancet Oncol · 2012 · Derived
    PubMed: PMID 22277837 · NCT00556322 · Carcinoma, Non-Small-Cell Lung
  19. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z, Lee JC, Lin L, et al. · Nat Genet · 2012 · Background
    PubMed: PMID 22751098 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  20. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
    Witta SE, Jotte RM, Konduri K, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22508830 · NCT01594398 (ENCORE110) · Carcinoma, Non-Small-Cell Lung
  21. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
    Tsao MN, Lloyd N, Wong RK, et al. · Cochrane Database Syst Rev · 2012 · Background
    PubMed: PMID 22513917 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  22. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
    Togashi Y, Masago K, Masuda S, et al. · Cancer Chemother Pharmacol · 2012 · Background
    PubMed: PMID 22806307 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  23. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.
    Reinholz MM, Kitzmann KA, Tenner K, et al. · Clin Cancer Res · 2012 · Background
    PubMed: PMID 21976532 · NCT00059852 · Breast Neoplasms
  24. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).
    Pesce GA, Klingbiel D, Ribi K, et al. · Eur J Cancer · 2012 · Background
    PubMed: PMID 22093943 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  25. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ, Kim HT, Lee DH, et al. · Lung Cancer · 2012 · Background
    PubMed: PMID 22677429 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  26. The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review).
    Modjtahedi H, Dean C · Int J Oncol · 2012 · Background
    PubMed: PMID 21566922 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  27. β-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells.
    Liu J, Hu XJ, Jin B, et al. · J Pharm Pharmacol · 2012 · Background
    PubMed: PMID 22150682 · NCT03123484 · Carcinoma, Non-Small-Cell Lung
  28. Axl-dependent signalling: a clinical update.
    Korshunov VA · Clin Sci (Lond) · 2012 · Background
    PubMed: PMID 22187964 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  29. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
    Hainsworth JD, Spigel DR, Greco FA, et al. · Cancer J · 2012 · Background
    PubMed: PMID 21952273 · NCT00392704 · Head and Neck Neoplasms
  30. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
    Conradt L, Godl K, Schaab C, et al. · Neoplasia · 2012 · Background
    PubMed: PMID 22131878 · NCT06161558 · Neoplasms

2011 (26 papers)

  1. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
    Niu Q, Wang W, Li Y, et al. · Int Immunopharmacol · 2011 · Trial result
    PubMed: PMID 21215350 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
    Natale RB, Thongprasert S, Greco FA, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21282542 · NCT00364351 · Carcinoma, Non-Small-Cell Lung
  3. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
    Kim H, Kim SH, Kim MJ, et al. · J Immunother · 2011 · Trial result
    PubMed: PMID 21499124 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.
    Kao J, Genden EM, Chen CT, et al. · Cancer · 2011 · Trial result
    PubMed: PMID 21246519 · NCT00970502 · Head and Neck Neoplasms
  5. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM, Shroff RT, Xiong H, et al. · BMC Cancer · 2011 · Trial result
    PubMed: PMID 20630061 · NCT00640978 · Pancreatic Neoplasms
  6. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M, Wu YL, Thongprasert S, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21670455 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  7. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
    Bullock KE, Petros WP, Younis I, et al. · Cancer Chemother Pharmacol · 2011 · Trial result
    PubMed: PMID 21079958 · NCT00276575
  8. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.
    Bour-Jordan H, Esensten JH, Martinez-Llordella M, et al. · Immunol Rev · 2011 · Trial result
    PubMed: PMID 21488898 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  9. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Zhou C, Wu YL, Chen G, et al. · Lancet Oncol · 2011 · Derived
    PubMed: PMID 21783417 · NCT00874419 (ML20981) · Carcinoma, Non-Small-Cell Lung
  10. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
    White-Koning M, Civade E, Geoerger B, et al. · Clin Cancer Res · 2011 · Derived
    PubMed: PMID 21653689 · NCT00418327 · Brain Neoplasms
  11. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
    Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. · Mol Cancer Ther · 2011 · Derived
    PubMed: PMID 21135251 · NCT00276744 · Pancreatic Neoplasms
  12. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
    Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. · Neuro Oncol · 2011 · Derived
    PubMed: PMID 20716591 · NCT00671970 · Brain Neoplasms
  13. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
    Herbst RS, Ansari R, Bustin F, et al. · Lancet · 2011 · Derived
    PubMed: PMID 21621716 · NCT00130728 · Carcinoma, Non-Small-Cell Lung
  14. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
    Farina G, Longo F, Martelli O, et al. · Clin Lung Cancer · 2011 · Derived
    PubMed: PMID 21550561 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  15. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.
    Wang M, Morsbach F, Sander D, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21852385 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  16. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Togashi Y, Masago K, Fukudo M, et al. · Cancer Chemother Pharmacol · 2011 · Background
    PubMed: PMID 21681573 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  17. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21576636 · NCT00600015 · Carcinoma, Non-Small-Cell Lung
  18. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
    Rizvi NA, Rusch V, Pao W, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21558399 · NCT01407822 (EMERGING) · Carcinoma, Non-Small-Cell Lung
  19. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
    Porta R, Sánchez-Torres JM, Paz-Ares L, et al. · Eur Respir J · 2011 · Background
    PubMed: PMID 20595147 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  20. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis.
    Minniti G, Clarke E, Lanzetta G, et al. · Radiat Oncol · 2011 · Background
    PubMed: PMID 21575163 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  21. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.
    Kocher M, Soffietti R, Abacioglu U, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21041710 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  22. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
    Keedy VL, Temin S, Somerfield MR, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21482992 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  23. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
    Horgan AM, Bradbury PA, Amir E, et al. · Ann Oncol · 2011 · Background
    PubMed: PMID 21273345 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  24. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
    Hector A, Montgomery EA, Karikari C, et al. · Cancer Biol Ther · 2011 · Background
    PubMed: PMID 20818175 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  25. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.
    Haura EB, Sommers E, Song L, et al. · J Thorac Oncol · 2011 · Background
    PubMed: PMID 20881637 · NCT01407822 (EMERGING) · Carcinoma, Non-Small-Cell Lung
  26. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
    Chambers SK, Clouser MC, Baker AF, et al. · Clin Cancer Res · 2011 · Background
    PubMed: PMID 21041183 · NCT00130520 · Ovarian Neoplasms

2010 (20 papers)

  1. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
    Reardon DA, Desjardins A, Vredenburgh JJ, et al. · J Neurooncol · 2010 · Trial result
    PubMed: PMID 19562254 · NCT00672243 · Brain Neoplasms
  2. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
    Quintela-Fandino M, Le Tourneau C, Duran I, et al. · Mol Cancer Ther · 2010 · Trial result
    PubMed: PMID 20197396 · NCT00126620
  3. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
    Pruthi RS, Nielsen M, Heathcote S, et al. · BJU Int · 2010 · Trial result
    PubMed: PMID 20089114 · NCT00380029 · Urinary Bladder Neoplasms
  4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M, Inoue A, Kobayashi K, et al. · N Engl J Med · 2010 · Trial result
    PubMed: PMID 20573926 · NCT02759614
  5. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    Ko AH, Venook AP, Bergsland EK, et al. · Cancer Chemother Pharmacol · 2010 · Trial result
    PubMed: PMID 20130876 · NCT00365144 · Pancreatic Neoplasms
  6. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    Kantoff PW, Higano CS, Shore ND, et al. · N Engl J Med · 2010 · Trial result
    PubMed: PMID 20818862 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  7. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
    Hainsworth JD, Spigel DR, Thompson DS, et al. · Oncologist · 2010 · Trial result
    PubMed: PMID 19965914 · NCT00360360 · Neoplasms, Unknown Primary
  8. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.
    Gutiérrez-Gutiérrez G, Sereno M, Miralles A, et al. · Clin Transl Oncol · 2010 · Trial result
    PubMed: PMID 20156778 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  9. Dynamic contrast enhanced-MRI in head and neck cancer patients: variability of the precontrast longitudinal relaxation time (T10).
    Craciunescu O, Brizel D, Cleland E, et al. · Med Phys · 2010 · Trial result
    PubMed: PMID 20632579 · NCT00140556 · Head and Neck Neoplasms
  10. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
    Blank SV, Christos P, Curtin JP, et al. · Gynecol Oncol · 2010 · Trial result
    PubMed: PMID 20837357 · NCT00059787 · Carcinoma, Ovarian Epithelial
  11. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F, Ciuleanu T, Stelmakh L, et al. · Lancet Oncol · 2010 · Derived
    PubMed: PMID 20493771 · NCT00556712 · Carcinoma, Non-Small-Cell Lung
  12. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
    Raizer JJ, Abrey LE, Lassman AB, et al. · Neuro Oncol · 2010 · Background
    PubMed: PMID 20150371 · NCT00045110 · Brain Neoplasms
  13. Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis.
    Neyns B, Meert V, Vandenbroucke F, et al. · Curr Oncol · 2010 · Background
    PubMed: PMID 18769609 · NCT01006096 · Psoriasis
  14. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
    Lee DH, Park K, Kim JH, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 20145166 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  15. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.
    Kummar S, Chen HX, Wright J, et al. · Nat Rev Drug Discov · 2010 · Background
    PubMed: PMID 21031001 · NCT06161558 · Neoplasms
  16. Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival.
    Frazier JL, Batra S, Kapor S, et al. · Int J Radiat Oncol Biol Phys · 2010 · Background
    PubMed: PMID 19619958 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  17. The developing role for intensity-modulated radiation therapy (IMRT) in the non-surgical treatment of brain metastases.
    Edwards AA, Keggin E, Plowman PN, et al. · Br J Radiol · 2010 · Background
    PubMed: PMID 20019176 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  18. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY, Shepherd FA, Hirsh V, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20038723 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  19. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
    Di Nicolantonio F, Arena S, Tabernero J, et al. · J Clin Invest · 2010 · Background
    PubMed: PMID 20664172 · NCT00770263
  20. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery.
    Blonigen BJ, Steinmetz RD, Levin L, et al. · Int J Radiat Oncol Biol Phys · 2010 · Background
    PubMed: PMID 19783374 · NCT02556593 · Carcinoma, Non-Small-Cell Lung

2009 (17 papers)

  1. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
    van den Bent MJ, Brandes AA, Rampling R, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19204207 · NCT00086879 · Brain Neoplasms
  2. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
    Riely GJ, Rizvi NA, Kris MG, et al. · J Clin Oncol · 2009 · Trial result
    PubMed: PMID 19047285 · NCT00287989 · Carcinoma, Non-Small-Cell Lung
  3. Skin metastases from lung cancer.
    Mollet TW, Garcia CA, Koester G, et al. · Dermatol Online J · 2009 · Trial result
    PubMed: PMID 19624979 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  4. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
    Dickler MN, Cobleigh MA, Miller KD, et al. · Breast Cancer Res Treat · 2009 · Trial result
    PubMed: PMID 18496750 · NCT00109265 · Neoplasms
  5. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
    Davies AM, Ho C, Beckett L, et al. · J Thorac Oncol · 2009 · Trial result
    PubMed: PMID 19494788 · NCT00387322 · Carcinoma, Non-Small-Cell Lung
  6. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
    Britten CD, Finn RS, Bosserman LD, et al. · Clin Breast Cancer · 2009 · Trial result
    PubMed: PMID 19299235 · NCT00033514 · Breast Neoplasms
  7. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
    Rosell R, Perez-Roca L, Sanchez JJ, et al. · PLoS One · 2009 · Derived
    PubMed: PMID 19415121 · NCT00883480 (SLAT) · Carcinoma, Non-Small-Cell Lung
  8. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
    Cohen EE, Davis DW, Karrison TG, et al. · Lancet Oncol · 2009 · Derived
    PubMed: PMID 19201650 · NCT00055913 · Squamous Cell Carcinoma of Head and Neck
  9. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
    Brown PD, Krishnan S, Sarkaria JN, et al. · J Clin Oncol · 2009 · Derived
    PubMed: PMID 18955445 · NCT00039494 · Glioblastoma
  10. Gamma knife radiosurgery for multiple brain metastases from lung cancer.
    Park SH, Hwang SK, Kang DH, et al. · J Clin Neurosci · 2009 · Background
    PubMed: PMID 19268596 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  11. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    Mok TS, Wu YL, Thongprasert S, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19692680 · NCT00600587 · Carcinoma, Non-Small-Cell Lung
  12. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
    Liu L, Greger J, Shi H, et al. · Cancer Res · 2009 · Background
    PubMed: PMID 19671800 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  13. Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy.
    Lagerwaard FJ, van der Hoorn EA, Verbakel WF, et al. · Int J Radiat Oncol Biol Phys · 2009 · Background
    PubMed: PMID 19577856 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  14. Cancer statistics, 2009.
    Jemal A, Siegel R, Ward E, et al. · CA Cancer J Clin · 2009 · Background
    PubMed: PMID 19474385 · NCT01229150 · Carcinoma, Non-Small-Cell Lung
  15. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT02424617 · Carcinoma, Non-Small-Cell Lung
  16. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
    Di Maio M, Chiodini P, Georgoulias V, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19273711 · NCT01652469 (EMPHASIS) · Carcinoma, Non-Small-Cell Lung
  17. A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision.
    Davey P, Hoegler D, Ennis M, et al. · Radiother Oncol · 2009 · Background
    PubMed: PMID 18555546 · NCT02556593 · Carcinoma, Non-Small-Cell Lung

2008 (23 papers)

  1. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
    Spigel DR, Lin M, O'Neill V, et al. · Cancer · 2008 · Trial result
    PubMed: PMID 18438878 · NCT00091663 · Carcinoma, Non-Small-Cell Lung
  2. Epitope landscape in breast and colorectal cancer.
    Segal NH, Parsons DW, Peggs KS, et al. · Cancer Res · 2008 · Trial result
    PubMed: PMID 18245491 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
    Oza AM, Eisenhauer EA, Elit L, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18591547 · NCT00030485 · Endometrial Neoplasms
  4. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R, Axelrod R, Thomas S, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18281658 · NCT00085839 · Carcinoma, Non-Small-Cell Lung
  5. Next generation of immunotherapy for melanoma.
    Kirkwood JM, Tarhini AA, Panelli MC, et al. · J Clin Oncol · 2008 · Trial result
    PubMed: PMID 18612161 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  6. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
    Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al. · Clin Cancer Res · 2008 · Trial result
    PubMed: PMID 18829515 · NCT00047736 · Carcinoma, Non-Small-Cell Lung
  7. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD, Spigel DR, Sosman JA, et al. · Clin Genitourin Cancer · 2008 · Trial result
    PubMed: PMID 18272024 · NCT00193258 · Carcinoma, Renal Cell
  8. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
    Yang CH, Yu CJ, Shih JY, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18509184 · NCT01024413 · Lung Neoplasms
  9. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.
    Tanaka T, Munshi A, Brooks C, et al. · Clin Cancer Res · 2008 · Background
    PubMed: PMID 18281562 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  10. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
    Takamochi K, Suzuki K, Sugimura H, et al. · Lung Cancer · 2008 · Background
    PubMed: PMID 17548126 · NCT00600587 · Carcinoma, Non-Small-Cell Lung
  11. Erlotinib: the first biologic in the management of pancreatic cancer.
    Saif MW · Expert Opin Pharmacother · 2008 · Background
    PubMed: PMID 18518788 · NCT00770263
  12. Reduction of overall treatment time in patients irradiated for more than three brain metastases.
    Rades D, Kieckebusch S, Lohynska R, et al. · Int J Radiat Oncol Biol Phys · 2008 · Background
    PubMed: PMID 17689033 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  13. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
    Pandya KJ, Dahlberg S, Hidalgo M, et al. · J Thorac Oncol · 2008 · Background
    PubMed: PMID 17975496 · NCT00770263
  14. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
    Meany HJ, Fox E, McCully C, et al. · Cancer Chemother Pharmacol · 2008 · Background
    PubMed: PMID 17932674 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  15. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
    Maruyama R, Nishiwaki Y, Tamura T, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18779611 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  16. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES, Hirsh V, Mok T, et al. · Lancet · 2008 · Background
    PubMed: PMID 19027483 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  17. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.
    Kappers I, Klomp HM, Burgers JA, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18757336 · NCT01407822 (EMERGING) · Carcinoma, Non-Small-Cell Lung
  18. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
    Halin C, Fahrngruber H, Meingassner JG, et al. · Am J Pathol · 2008 · Background
    PubMed: PMID 18535184 · NCT01006096 · Psoriasis
  19. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S, Ostman A, Rollman O, et al. · Arch Dermatol Res · 2008 · Background
    PubMed: PMID 18446355 · NCT01006096 · Psoriasis
  20. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
    Costa DB, Schumer ST, Tenen DG, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18309959 · NCT01024413 · Lung Neoplasms
  21. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
    Costa DB, Kobayashi S, Tenen DG, et al. · Lung Cancer · 2008 · Background
    PubMed: PMID 17610986 · NCT00600587 · Carcinoma, Non-Small-Cell Lung
  22. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
    Azzariti A, Porcelli L, Gatti G, et al. · Biochem Pharmacol · 2008 · Background
    PubMed: PMID 18191814 · NCT00770263
  23. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA, Cohen RB, Franklin W, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18390968 · NCT01306045 · Carcinoma, Non-Small-Cell Lung

2007 (24 papers)

  1. Potential therapeutic role of natural killer cells in cancer.
    Woan K, Reddy V · Expert Opin Biol Ther · 2007 · Trial result
    PubMed: PMID 17150016 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
    Siu LL, Soulieres D, Chen EX, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17538162 · NCT00030576 · Squamous Cell Carcinoma of Head and Neck
  3. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL, Krysan K, Morrow JD, et al. · Clin Cancer Res · 2007 · Trial result
    PubMed: PMID 16740761 · NCT00072072 · Carcinoma, Non-Small-Cell Lung
  4. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ, Goldstein D, Hamm J, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17452677 · NCT00026338 · Pancreatic Neoplasms
  5. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Spigel DR, Farley C, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17470864 · NCT00193622 · Neoplasms, Unknown Primary
  6. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
    Duran I, Hotté SJ, Hirte H, et al. · Clin Cancer Res · 2007 · Trial result
    PubMed: PMID 17699864 · NCT00126620
  7. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
    Bukowski RM, Kabbinavar FF, Figlin RA, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17876014 · NCT00081614 · Neoplasm Metastasis
  8. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
    Agulnik M, da Cunha Santos G, Hedley D, et al. · J Clin Oncol · 2007 · Trial result
    PubMed: PMID 17538163 · NCT00030576 · Squamous Cell Carcinoma of Head and Neck
  9. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.
    Yildiz PB, Shyr Y, Rahman JS, et al. · J Thorac Oncol · 2007 · Background
    PubMed: PMID 17909350 · NCT01652469 (EMPHASIS) · Carcinoma, Non-Small-Cell Lung
  10. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
    Wu YL, Zhong WZ, Li LY, et al. · J Thorac Oncol · 2007 · Background
    PubMed: PMID 17473659 · NCT00600587 · Carcinoma, Non-Small-Cell Lung
  11. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
    van Zandwijk N, Mathy A, Boerrigter L, et al. · Ann Oncol · 2007 · Background
    PubMed: PMID 17060486 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  12. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
    Taguchi F, Solomon B, Gregorc V, et al. · J Natl Cancer Inst · 2007 · Background
    PubMed: PMID 17551144 · NCT01652469 (EMPHASIS) · Carcinoma, Non-Small-Cell Lung
  13. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
    Sequist LV, Joshi VA, Jänne PA, et al. · Oncologist · 2007 · Background
    PubMed: PMID 17285735 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  14. Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
    Reck M, Buchholz E, Romer KS, et al. · Clin Lung Cancer · 2007 · Background
    PubMed: PMID 16800967 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  15. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome.
    Merino MJ, Torres-Cabala C, Pinto P, et al. · Am J Surg Pathol · 2007 · Background
    PubMed: PMID 17895761 · NCT01130519 · Carcinoma, Renal Cell
  16. Pathogenesis and therapy of psoriasis.
    Lowes MA, Bowcock AM, Krueger JG, et al. · Nature · 2007 · Background
    PubMed: PMID 17314973 · NCT01006096 · Psoriasis
  17. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
    Jimeno A, Kulesza P, Wheelhouse J, et al. · Br J Cancer · 2007 · Background
    PubMed: PMID 17342092 · NCT00770263
  18. Cancer statistics, 2007.
    Jemal A, Siegel R, Ward E, et al. · CA Cancer J Clin · 2007 · Background
    PubMed: PMID 17237035 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  19. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM, Yeap BY, Sequist LV, et al. · Clin Cancer Res · 2007 · Background
    PubMed: PMID 16818686 · NCT01024413 · Lung Neoplasms
  20. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
    Jackman DM, Yeap BY, Lindeman NI, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17228019 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  21. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G, Carducci M, Tomczak P, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 17538086 · NCT00770263
  22. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
    Gatzemeier U, Pluzanska A, Szczesna A, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17442998 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  23. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E, Eyzaguirre A, Brown E, et al. · Mol Cancer Ther · 2007 · Background
    PubMed: PMID 17121914 · NCT00770263
  24. Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain metastases.
    Bauman G, Yartsev S, Fisher B, et al. · Am J Clin Oncol · 2007 · Background
    PubMed: PMID 17278893 · NCT02556593 · Carcinoma, Non-Small-Cell Lung

2006 (22 papers)

  1. Natural killer T cell-mediated antitumor immune responses and their clinical applications.
    Seino K, Motohashi S, Fujisawa T, et al. · Cancer Sci · 2006 · Trial result
    PubMed: PMID 16805854 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Cancer stem cells.
    Jordan CT, Guzman ML, Noble M, et al. · N Engl J Med · 2006 · Trial result
    PubMed: PMID 16990388 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
    Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. · J Clin Oncol · 2006 · Trial result
    PubMed: PMID 17050876 · NCT00032123 · Esophageal Neoplasms
  4. [Bronchioloalveolar carcinoma].
    Wislez M, Gounant V, Cadranel J, et al. · Rev Mal Respir · 2006 · Background
    PubMed: PMID 16340839 · NCT00384826 · Adenocarcinoma, Bronchiolo-Alveolar
  5. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
    Wierzbicka E, Tourani JM, Guillet G, et al. · Br J Dermatol · 2006 · Background
    PubMed: PMID 16792781 · NCT01006096 · Psoriasis
  6. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer.
    Wei MH, Toure O, Glenn GM, et al. · J Med Genet · 2006 · Background
    PubMed: PMID 15937070 · NCT01130519 · Carcinoma, Renal Cell
  7. Targeted therapies for esophageal cancer.
    Tew WP, Kelsen DP, Ilson DH, et al. · Oncologist · 2006 · Background
    PubMed: PMID 16177283 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  8. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.
    Teachey DT, Obzut DA, Cooperman J, et al. · Blood · 2006 · Background
    PubMed: PMID 16195324 · NCT00770263
  9. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
    Salama JK, Vokes EE, Chmura SJ, et al. · Int J Radiat Oncol Biol Phys · 2006 · Background
    PubMed: PMID 16213104 · NCT00970502 · Head and Neck Neoplasms
  10. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ, Pao W, Pham D, et al. · Clin Cancer Res · 2006 · Background
    PubMed: PMID 16467097 · NCT01024413 · Lung Neoplasms
  11. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
    Prados MD, Lamborn KR, Chang S, et al. · Neuro Oncol · 2006 · Background
    PubMed: PMID 16443950 · NCT00770263
  12. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
    Pao W, Miller VA, Politi KA, et al. · PLoS Med · 2006 · Background
    PubMed: PMID 15737014 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  13. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
    O'Reilly KE, Rojo F, She QB, et al. · Cancer Res · 2006 · Background
    PubMed: PMID 16452206 · NCT00770263
  14. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J, Baselga J · Semin Oncol · 2006 · Background
    PubMed: PMID 16890793 · NCT00770263
  15. Increased risk of cancer in patients with fumarate hydratase germline mutation.
    Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, et al. · J Med Genet · 2006 · Background
    PubMed: PMID 16155190 · NCT01130519 · Carcinoma, Renal Cell
  16. Mechanisms of cutaneous toxicities to EGFR inhibitors.
    Lacouture ME · Nat Rev Cancer · 2006 · Background
    PubMed: PMID 16990857 · NCT01006096 · Psoriasis
  17. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    Hirsch FR, Varella-Garcia M, Bunn PA, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 17075123 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  18. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
    Gordon AN, Finkler N, Edwards RP, et al. · Int J Gynecol Cancer · 2006 · Background
    PubMed: PMID 16174225 · NCT00770263
  19. Current development of mTOR inhibitors as anticancer agents.
    Faivre S, Kroemer G, Raymond E, et al. · Nat Rev Drug Discov · 2006 · Background
    PubMed: PMID 16883305 · NCT00770263
  20. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
    Chang SM, Wen P, Cloughesy T, et al. · Invest New Drugs · 2006 · Background
    PubMed: PMID 16012795 · NCT00770263
  21. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R, Melisi D, Ciardiello F, et al. · Eur J Cancer · 2006 · Background
    PubMed: PMID 16376541 · NCT00770263
  22. Stereotactic radiosurgery for four or more intracranial metastases.
    Bhatnagar AK, Flickinger JC, Kondziolka D, et al. · Int J Radiat Oncol Biol Phys · 2006 · Background
    PubMed: PMID 16338097 · NCT02556593 · Carcinoma, Non-Small-Cell Lung

2005 (39 papers)

  1. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.
    Ocean AJ, Vahdat LT · Support Care Cancer · 2005 · Trial result
    PubMed: PMID 15258838 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE, Geyer SM, Ghobrial I, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15983389 · NCT00770263
  3. mTOR-targeted therapy of cancer with rapamycin derivatives.
    Vignot S, Faivre S, Aguirre D, et al. · Ann Oncol · 2005 · Background
    PubMed: PMID 15728109 · NCT00770263
  4. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
    Tsao MS, Sakurada A, Cutz JC, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16014883 · NCT00036647 · Carcinoma, Non-Small-Cell Lung
  5. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
    Thatcher N, Chang A, Parikh P, et al. · Lancet · 2005 · Background
    PubMed: PMID 16257339 · NCT01024413 · Lung Neoplasms
  6. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M, Ichinose Y, Rosell R, et al. · Clin Cancer Res · 2005 · Background
    PubMed: PMID 16115929 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  7. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY, Rosenberg LM, Wang X, et al. · Cancer Res · 2005 · Background
    PubMed: PMID 16103051 · NCT00770263
  8. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16014882 · NCT00036647 · Carcinoma, Non-Small-Cell Lung
  9. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W, Nagel S, Blankenburg T, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 16293869 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  10. Clinical trial designs for predictive marker validation in cancer treatment trials.
    Sargent DJ, Conley BA, Allegra C, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15774793 · NCT01652469 (EMPHASIS) · Carcinoma, Non-Small-Cell Lung
  11. Targeting the molecular target of rapamycin (mTOR).
    Rowinsky EK · Curr Opin Oncol · 2005 · Background
    PubMed: PMID 15627018 · NCT00770263
  12. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
    Raizer JJ · J Neurooncol · 2005 · Background
    PubMed: PMID 16078112 · NCT00770263
  13. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    Peréz-Soler R, Saltz L · J Clin Oncol · 2005 · Background
    PubMed: PMID 16051966 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  14. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
    Pérez-Soler R, Delord JP, Halpern A, et al. · Oncologist · 2005 · Background
    PubMed: PMID 15851793 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  15. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group.
    Osoba D, Bezjak A, Brundage M, et al. · Eur J Cancer · 2005 · Background
    PubMed: PMID 15661554 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  16. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities.
    Miller VA, Hirsch FR, Johnson DH, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15886316 · NCT00770263
  17. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK, Wang MY, Vivanco I, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16282176 · NCT00301418 · Brain Neoplasms
  18. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
    Margolin K, Longmate J, Baratta T, et al. · Cancer · 2005 · Background
    PubMed: PMID 16007689 · NCT00770263
  19. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
    Marchetti A, Martella C, Felicioni L, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15681531 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  20. New treatments for metastatic kidney cancer.
    Mancuso A, Sternberg CN · Can J Urol · 2005 · Background
    PubMed: PMID 15780170 · NCT00770263
  21. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo.
    Leyton J, Latigo JR, Perumal M, et al. · Cancer Res · 2005 · Background
    PubMed: PMID 15899811 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  22. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
    Kobayashi S, Boggon TJ, Dayaram T, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 15728811 · NCT01562028 (BELIEF) · Carcinoma, Non-Small-Cell Lung
  23. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR, Cohen M, Sridhara R, et al. · Clin Cancer Res · 2005 · Background
    PubMed: PMID 16166415 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  24. Cancer statistics, 2005.
    Jemal A, Murray T, Ward E, et al. · CA Cancer J Clin · 2005 · Background
    PubMed: PMID 15661684 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  25. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A, Robak T, Smolewski P, et al. · Cell Mol Biol Lett · 2005 · Background
    PubMed: PMID 16217558 · NCT00770263
  26. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.
    Jänne PA, Engelman JA, Johnson BE, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15886310 · NCT00137839 · Carcinoma, Non-Small-Cell Lung
  27. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS, Prager D, Hermann R, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 16043829 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  28. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
    Gemmill RM, Zhou M, Costa L, et al. · Br J Cancer · 2005 · Background
    PubMed: PMID 15956968 · NCT00353301 · Carcinoma, Renal Cell
  29. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E, Buckner JC, Maurer MJ, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15998902 · NCT00770263
  30. Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy.
    Dewhirst MW, Poulson JM, Yu D, et al. · Int J Radiat Oncol Biol Phys · 2005 · Background
    PubMed: PMID 15667971 · NCT00140556 · Head and Neck Neoplasms
  31. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    DeGraffenried LA, Fulcher L, Friedrichs WE, et al. · Ann Oncol · 2005 · Background
    PubMed: PMID 15367412 · NCT00770263
  32. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
    D'Addario G, Pintilie M, Leighl NB, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15728229 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  33. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P, Huang S, Vallabhaneni G, et al. · Cancer Res · 2005 · Background
    PubMed: PMID 15833866 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  34. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S, Scheulen ME, Johnston S, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15955899 · NCT00770263
  35. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 16051952 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  36. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F, Hirsch FR, Rossi E, et al. · J Natl Cancer Inst · 2005 · Background
    PubMed: PMID 15870435 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  37. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW, Lynch TJ, Haserlat SM, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 16204011 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  38. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J, Arteaga CL · J Clin Oncol · 2005 · Background
    PubMed: PMID 15753456 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  39. Perturbations of the AKT signaling pathway in human cancer.
    Altomare DA, Testa JR · Oncogene · 2005 · Background
    PubMed: PMID 16288292 · NCT01306045 · Carcinoma, Non-Small-Cell Lung

2004 (26 papers)

  1. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
    Tan AR, Yang X, Hewitt SM, et al. · J Clin Oncol · 2004 · Trial result
    PubMed: PMID 15284258 · NCT00030537 · Breast Neoplasms
  2. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy.
    Trivin F, Boucher E, Raoul JL, et al. · Acta Oncol · 2004 · Background
    PubMed: PMID 15370619 · NCT01006096 · Psoriasis
  3. Multidisciplinary management of lung cancer.
    Spira A, Ettinger DS · N Engl J Med · 2004 · Background
    PubMed: PMID 14736930 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  4. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
    Soulieres D, Senzer NN, Vokes EE, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14701768 · NCT00770263
  5. Treatment of metastatic esophagus and gastric cancer.
    Shah MA, Schwartz GK · Semin Oncol · 2004 · Background
    PubMed: PMID 15297948 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  6. The biology of epidermal growth factor receptor in lung cancer.
    Scagliotti GV, Selvaggi G, Novello S, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 15217963 · NCT00462995 (SELECT) · Carcinoma, Non-Small-Cell Lung
  7. The biology and clinical relevance of the PTEN tumor suppressor pathway.
    Sansal I, Sellers WR · J Clin Oncol · 2004 · Background
    PubMed: PMID 15254063 · NCT00770263
  8. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
    Raymond E, Alexandre J, Faivre S, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 15136596 · NCT00770263
  9. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.
    Pfister DG, Johnson DH, Azzoli CG, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14691125 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  10. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
    Perez-Soler R · Clin Cancer Res · 2004 · Background
    PubMed: PMID 15217965 · NCT00770263
  11. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
    Pérez-Soler R, Chachoua A, Hammond LA, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 15310767 · NCT00137839 · Carcinoma, Non-Small-Cell Lung
  12. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
    Peralba JM, DeGraffenried L, Friedrichs W, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 12912932 · NCT00770263
  13. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
    Parra HS, Cavina R, Latteri F, et al. · Br J Cancer · 2004 · Background
    PubMed: PMID 15187994 · NCT00770263
  14. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
    Pao W, Miller V, Zakowski M, et al. · Proc Natl Acad Sci U S A · 2004 · Background
    PubMed: PMID 15329413 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  15. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
    Paez JG, Jänne PA, Lee JC, et al. · Science · 2004 · Background
    PubMed: PMID 15118125 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  16. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules.
    Moeller BJ, Cao Y, Li CY, et al. · Cancer Cell · 2004 · Background
    PubMed: PMID 15144951 · NCT00140556 · Head and Neck Neoplasms
  17. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    Lynch TJ, Bell DW, Sordella R, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15118073 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  18. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.
    Jager PL, Gietema JA, van der Graaf WT, et al. · Nucl Med Commun · 2004 · Background
    PubMed: PMID 15100500 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  19. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
    Hanna N, Shepherd FA, Fossella FV, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 15117980 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  20. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
    Giaccone G, Herbst RS, Manegold C, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14990632 · NCT01024413 · Lung Neoplasms
  21. Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
    Gatzemeier U · Oncology (Williston Park) · 2004 · Background
    PubMed: PMID 14682117 · NCT00770263
  22. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
    Ciardiello F, Caputo R, Damiano V, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 12684431 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  23. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F, Magrini E, Ceresoli GL, et al. · J Natl Cancer Inst · 2004 · Background
    PubMed: PMID 15292385 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  24. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer.
    Boffa DJ, Luan F, Thomas D, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 14734482 · NCT00770263
  25. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
    Atkins MB, Hidalgo M, Stadler WM, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 14990647 · NCT00770263
  26. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.
    Andrews DW, Scott CB, Sperduto PW, et al. · Lancet · 2004 · Background
    PubMed: PMID 15158627 · NCT02556593 · Carcinoma, Non-Small-Cell Lung

2003 (19 papers)

  1. Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment.
    Armstrong WB, Wan XS, Kennedy AR, et al. · Laryngoscope · 2003 · Trial result
    PubMed: PMID 14520092 · NCT00482625 · Pancreatic Neoplasms
  2. Clinical characteristics of pneumonic-type adenocarcinoma of the lung.
    Wislez M, Massiani MA, Milleron B, et al. · Chest · 2003 · Background
    PubMed: PMID 12796162 · NCT00384826 · Adenocarcinoma, Bronchiolo-Alveolar
  3. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA, Petersen V, Schmidt B, et al. · J Clin Oncol · 2003 · Background
    PubMed: PMID 12860940 · NCT00462995 (SELECT) · Carcinoma, Non-Small-Cell Lung
  4. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
    Stroobants S, Goeminne J, Seegers M, et al. · Eur J Cancer · 2003 · Background
    PubMed: PMID 12957455 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  5. Treatment of stage IIIA non-small cell lung cancer.
    Robinson LA, Wagner H, Ruckdeschel JC, et al. · Chest · 2003 · Background
    PubMed: PMID 12527580 · NCT00600587 · Carcinoma, Non-Small-Cell Lung
  6. Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control.
    Oldham S, Hafen E · Trends Cell Biol · 2003 · Background
    PubMed: PMID 12559758 · NCT00770263
  7. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
    Mendelsohn J, Baselga J · J Clin Oncol · 2003 · Background
    PubMed: PMID 12860957 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  8. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
    Lordick F, von Schilling C, Bernhard H, et al. · Br J Cancer · 2003 · Background
    PubMed: PMID 12915869 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  9. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    Kris MG, Natale RB, Herbst RS, et al. · JAMA · 2003 · Background
    PubMed: PMID 14570950 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  10. Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.
    Kao J, Garofalo MC, Milano MT, et al. · Cancer Treat Rev · 2003 · Background
    PubMed: PMID 12633577 · NCT00970502 · Head and Neck Neoplasms
  11. Dermatologic side effects associated with gefitinib therapy: clinical experience and management.
    Herbst RS, LoRusso PM, Purdom M, et al. · Clin Lung Cancer · 2003 · Background
    PubMed: PMID 14599302 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  12. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.
    Giralt J, Eraso A, Armengol M, et al. · Int J Radiat Oncol Biol Phys · 2003 · Background
    PubMed: PMID 12459370 · NCT00770263
  13. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
    Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. · Lancet Oncol · 2003 · Background
    PubMed: PMID 12573349 · NCT00770263
  14. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
    Fukuoka M, Yano S, Giaccone G, et al. · J Clin Oncol · 2003 · Background
    PubMed: PMID 12748244 · NCT01024413 · Lung Neoplasms
  15. CCI-779 Wyeth.
    Elit L · Curr Opin Investig Drugs · 2003 · Background
    PubMed: PMID 12211424 · NCT00770263
  16. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK, Halter G, Schirrmeister H, et al. · J Nucl Med · 2003 · Background
    PubMed: PMID 12960187 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  17. Four birds with one stone: RAPA as potential anticancer therapy.
    Blagosklonny MV, Darzynkiewicz Z · Cancer Biol Ther · 2003 · Background
    PubMed: PMID 12432246 · NCT00770263
  18. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
    Barthel H, Cleij MC, Collingridge DR, et al. · Cancer Res · 2003 · Background
    PubMed: PMID 12839975 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  19. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
    Allen LF, Sebolt-Leopold J, Meyer MB, et al. · Semin Oncol · 2003 · Background
    PubMed: PMID 14613031 · NCT01306045 · Carcinoma, Non-Small-Cell Lung

2002 (10 papers)

  1. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN, Gritzapis AD, Tsitsilonis OE, et al. · Int J Cancer · 2002 · Trial result
    PubMed: PMID 11948464 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.
    van Tinteren H, Hoekstra OS, Smit EF, et al. · Lancet · 2002 · Background
    PubMed: PMID 11978336 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  3. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
    Van Doorn R, Kirtschig G, Scheffer E, et al. · Br J Dermatol · 2002 · Background
    PubMed: PMID 12207609 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  4. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
    Schiller JH, Harrington D, Belani CP, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 11784875 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  5. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.
    Manning BD, Tee AR, Logsdon MN, et al. · Mol Cell · 2002 · Background
    PubMed: PMID 12150915 · NCT00770263
  6. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.
    Jung YD, Mansfield PF, Akagi M, et al. · Eur J Cancer · 2002 · Background
    PubMed: PMID 12008203 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  7. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
    Huang S, Houghton PJ · Curr Opin Investig Drugs · 2002 · Background
    PubMed: PMID 12020063 · NCT00770263
  8. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
    Hirata A, Ogawa S, Kometani T, et al. · Cancer Res · 2002 · Background
    PubMed: PMID 11980649 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  9. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus.
    Heath EI, Urba S, Marshall J, et al. · Invest New Drugs · 2002 · Background
    PubMed: PMID 12003198 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  10. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.
    Buck AK, Schirrmeister H, Hetzel M, et al. · Cancer Res · 2002 · Background
    PubMed: PMID 12067968 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung

2001 (14 papers)

  1. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
    Small EJ, Fratesi P, Reese DM, et al. · J Clin Oncol · 2001 · Trial result
    PubMed: PMID 11099318 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
    Yu K, Toral-Barza L, Discafani C, et al. · Endocr Relat Cancer · 2001 · Background
    PubMed: PMID 11566616 · NCT00770263
  3. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors.
    Shaheen RM, Ahmad SA, Liu W, et al. · Br J Cancer · 2001 · Background
    PubMed: PMID 11506500 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  4. Gamma knife treatment for multiple metastatic brain tumors compared with whole-brain radiation therapy.
    Serizawa T, Iuchi T, Ono J, et al. · J Neurosurg · 2001 · Background
    PubMed: PMID 11143259 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  5. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J, Cortes J, Calvo E, et al. · Cancer · 2001 · Background
    PubMed: PMID 11135224 · NCT01229150 · Carcinoma, Non-Small-Cell Lung
  6. Estimating the world cancer burden: Globocan 2000.
    Parkin DM, Bray F, Ferlay J, et al. · Int J Cancer · 2001 · Background
    PubMed: PMID 11668491 · NCT00462995 (SELECT) · Carcinoma, Non-Small-Cell Lung
  7. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Hidalgo M, Siu LL, Nemunaitis J, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11432895 · NCT00770263
  8. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M, Rowinsky EK · Oncogene · 2001 · Background
    PubMed: PMID 11426655 · NCT00770263
  9. Cancer statistics, 2001.
    Greenlee RT, Hill-Harmon MB, Murray T, et al. · CA Cancer J Clin · 2001 · Background
    PubMed: PMID 11577478 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung
  10. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
    Geoerger B, Kerr K, Tang CB, et al. · Cancer Res · 2001 · Background
    PubMed: PMID 11245461 · NCT00770263
  11. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
    Dudkin L, Dilling MB, Cheshire PJ, et al. · Clin Cancer Res · 2001 · Background
    PubMed: PMID 11410517 · NCT00770263
  12. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225.
    Busam KJ, Capodieci P, Motzer R, et al. · Br J Dermatol · 2001 · Background
    PubMed: PMID 11422037 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  13. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer.
    Brizel DM, Schroeder T, Scher RL, et al. · Int J Radiat Oncol Biol Phys · 2001 · Background
    PubMed: PMID 11567808 · NCT00140556 · Head and Neck Neoplasms
  14. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
    Brabender J, Danenberg KD, Metzger R, et al. · Clin Cancer Res · 2001 · Background
    PubMed: PMID 11448895 · NCT00770263

2000 (10 papers)

  1. The impact of 5-FU-based bolus chemotherapy on survival in patients with advanced colorectal cancer.
    Van Halteren HK, Roumen RM, Coebergh JW, et al. · Anticancer Res · 2000 · Background
    PubMed: PMID 10629633 · NCT00459901 · Colorectal Neoplasms
  2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. · J Natl Cancer Inst · 2000 · Background
    PubMed: PMID 10655437 · NCT00696696 · Pancreatic Neoplasms
  3. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
    Shepherd FA, Dancey J, Ramlau R, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10811675 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  4. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.
    Shaw E, Scott C, Souhami L, et al. · Int J Radiat Oncol Biol Phys · 2000 · Background
    PubMed: PMID 10802351 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  5. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.
    Powell TJ, Ben-Bassat H, Klein BY, et al. · Br J Dermatol · 2000 · Background
    PubMed: PMID 10583160 · NCT01006096 · Psoriasis
  6. Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
    Pieterman RM, van Putten JW, Meuzelaar JJ, et al. · N Engl J Med · 2000 · Background
    PubMed: PMID 10911007 · NCT00568841 (ERLOPET) · Carcinoma, Non-Small-Cell Lung
  7. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome.
    Brizel DM, Dodge RK, Clough RW, et al. · Radiother Oncol · 2000 · Background
    PubMed: PMID 10665787 · NCT00140556 · Head and Neck Neoplasms
  8. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
    Borgström P, Gold DP, Hillan KJ, et al. · Anticancer Res · 2000 · Background
    PubMed: PMID 10628376 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  9. Inhibitors of tyrosine kinases in the treatment of psoriasis.
    Ben-Bassat H, Levitzki A · Isr Med Assoc J · 2000 · Background
    PubMed: PMID 10909421 · NCT01006096 · Psoriasis
  10. Inhibitors of tyrosine kinases in the treatment of psoriasis.
    Ben-Bassat H, Klein BY · Curr Pharm Des · 2000 · Background
    PubMed: PMID 10828317 · NCT01006096 · Psoriasis

1999 (6 papers)

  1. The epidermal growth factor receptor and its inhibition in cancer therapy.
    Woodburn JR · Pharmacol Ther · 1999 · Background
    PubMed: PMID 10454201 · NCT00770263
  2. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
    Rusch V, Klimstra D, Venkatraman E, et al. · Clin Cancer Res · 1999 · Background
    PubMed: PMID 9815714 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  3. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group.
    Reissmann PT, Koga H, Figlin RA, et al. · J Cancer Res Clin Oncol · 1999 · Background
    PubMed: PMID 10190311 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  4. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
    Lei W, Mayotte JE, Levitt ML, et al. · Anticancer Res · 1999 · Background
    PubMed: PMID 10226546 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  5. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases.
    Kondziolka D, Patel A, Lunsford LD, et al. · Int J Radiat Oncol Biol Phys · 1999 · Background
    PubMed: PMID 10487566 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  6. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
    Fry DW · Pharmacol Ther · 1999 · Background
    PubMed: PMID 10454198 · NCT00770263

1998 (3 papers)

  1. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
    Sekine I, Takami S, Guang SG, et al. · Oncol Rep · 1998 · Background
    PubMed: PMID 9468555 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  2. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    Petit AM, Rak J, Hung MC, et al. · Am J Pathol · 1998 · Background
    PubMed: PMID 9403702 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  3. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.
    Brizel DM, Albers ME, Fisher SR, et al. · N Engl J Med · 1998 · Background
    PubMed: PMID 9632446 · NCT00140556 · Head and Neck Neoplasms

1997 (7 papers)

  1. The emerging role of CTLA-4 as an immune attenuator.
    Thompson CB, Allison JP · Immunity · 1997 · Trial result
    PubMed: PMID 9354465 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
    Perez VL, Van Parijs L, Biuckians A, et al. · Immunity · 1997 · Trial result
    PubMed: PMID 9133420 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  3. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns.
    Wosikowski K, Schuurhuis D, Johnson K, et al. · J Natl Cancer Inst · 1997 · Background
    PubMed: PMID 9337347 · NCT00770263
  4. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors.
    Rusch V, Mendelsohn J, Dmitrovsky E, et al. · Cytokine Growth Factor Rev · 1997 · Background
    PubMed: PMID 8899291 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  5. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
    Presta LG, Chen H, O'Connor SJ, et al. · Cancer Res · 1997 · Background
    PubMed: PMID 9377574 · NCT00442507 (OSI3650) · Esophageal Neoplasms
  6. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.
    Fujino S, Enokibori T, Tezuka N, et al. · Eur J Cancer · 1997 · Background
    PubMed: PMID 9014747 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  7. Vascular endothelial growth factor: basic biology and clinical implications.
    Ferrara N, Keyt B · EXS · 1997 · Background
    PubMed: PMID 9002234 · NCT00442507 (OSI3650) · Esophageal Neoplasms

1996 (4 papers)

  1. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.
    Pfeiffer P, Clausen PP, Andersen K, et al. · Br J Cancer · 1996 · Background
    PubMed: PMID 8679464 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  2. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
    Lorenz MC, Heitman J · J Biol Chem · 1996 · Background
    PubMed: PMID 7499212 · NCT00770263
  3. Targeting the epidermal growth factor receptor for therapy of carcinomas.
    Davies DE, Chamberlin SG · Biochem Pharmacol · 1996 · Background
    PubMed: PMID 8645330 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  4. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.
    Conroy T, Etienne PL, Adenis A, et al. · J Clin Oncol · 1996 · Background
    PubMed: PMID 8558192 · NCT00442507 (OSI3650) · Esophageal Neoplasms

1995 (6 papers)

  1. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
    Waterhouse P, Penninger JM, Timms E, et al. · Science · 1995 · Trial result
    PubMed: PMID 7481803 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. Epidermal growth factor-related peptides and their receptors in human malignancies.
    Salomon DS, Brandt R, Ciardiello F, et al. · Crit Rev Oncol Hematol · 1995 · Background
    PubMed: PMID 7612182 · NCT00770263
  3. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
    Sabers CJ, Martin MM, Brunn GJ, et al. · J Biol Chem · 1995 · Background
    PubMed: PMID 7822316 · NCT00770263
  4. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype.
    Fontanini G, Vignati S, Bigini D, et al. · Eur J Cancer · 1995 · Background
    PubMed: PMID 7718322 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  5. Chemotherapy for non-small cell lung cancer.
    Carbone DP, Minna JD · BMJ · 1995 · Background
    PubMed: PMID 7580533 · NCT01229150 · Carcinoma, Non-Small-Cell Lung
  6. Tyrphostins suppress the growth of psoriatic keratinocytes.
    Ben-Bassat H, Vardi DV, Gazit A, et al. · Exp Dermatol · 1995 · Background
    PubMed: PMID 7640880 · NCT01006096 · Psoriasis

1994 (2 papers)

  1. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients.
    Fox SB, Smith K, Hollyer J, et al. · Breast Cancer Res Treat · 1994 · Background
    PubMed: PMID 8018963 · NCT00770263
  2. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
    Bergman B, Aaronson NK, Ahmedzai S, et al. · Eur J Cancer · 1994 · Background
    PubMed: PMID 8080679 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung

1993 (4 papers)

  1. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival.
    Veale D, Kerr N, Gibson GJ, et al. · Br J Cancer · 1993 · Background
    PubMed: PMID 8391303 · NCT00473083 (LUTRAERL) · Lung Neoplasms
  2. Evidence for a role of EGF receptor in the progression of human lung carcinoma.
    Pavelic K, Banjac Z, Pavelic J, et al. · Anticancer Res · 1993 · Background
    PubMed: PMID 8394672 · NCT00462995 (SELECT) · Carcinoma, Non-Small-Cell Lung
  3. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases.
    Haie-Meder C, Pellae-Cosset B, Laplanche A, et al. · Radiother Oncol · 1993 · Background
    PubMed: PMID 7681997 · NCT02556593 · Carcinoma, Non-Small-Cell Lung
  4. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
    Aaronson NK, Ahmedzai S, Bergman B, et al. · J Natl Cancer Inst · 1993 · Background
    PubMed: PMID 8433390 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung

1992 (1 paper)

  1. Epidermal growth factor receptor and bladder cancer: a review.
    Neal DE, Mellon K · Urol Int · 1992 · Background
    PubMed: PMID 1357809 · NCT00770263

1990 (2 papers)

  1. Second cancers and other late side effects of cancer treatment. A review.
    Boivin JF · Cancer · 1990 · Trial result
    PubMed: PMID 2406000 · NCT07271446 · Carcinoma, Non-Small-Cell Lung
  2. What is the evidence that tumors are angiogenesis dependent?
    Folkman J · J Natl Cancer Inst · 1990 · Background
    PubMed: PMID 1688381 · NCT00442507 (OSI3650) · Esophageal Neoplasms

1989 (2 papers)

  1. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells.
    Meyers MB, Shen WP, Spengler BA, et al. · J Cell Biochem · 1989 · Background
    PubMed: PMID 2464605 · NCT00770263
  2. Ordinal regression models for epidemiologic data.
    Armstrong BG, Sloan M · Am J Epidemiol · 1989 · Background
    PubMed: PMID 2910061 · NCT00637910 (TAILOR) · Carcinoma, Non-Small-Cell Lung

1987 (1 paper)

  1. Epidermal growth factor receptors in non-small cell lung cancer.
    Veale D, Ashcroft T, Marsh C, et al. · Br J Cancer · 1987 · Background
    PubMed: PMID 3038157 · NCT00473083 (LUTRAERL) · Lung Neoplasms

1986 (1 paper)

  1. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours.
    Cerny T, Barnes DM, Hasleton P, et al. · Br J Cancer · 1986 · Background
    PubMed: PMID 3017396 · NCT00473083 (LUTRAERL) · Lung Neoplasms

1983 (1 paper)

  1. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
    Oken MM, Creech RH, Tormey DC, et al. · Am J Clin Oncol · 1983 · Background
    PubMed: PMID 7165009 · NCT02424617 · Carcinoma, Non-Small-Cell Lung

1978 (1 paper)

  1. [Quantitative description of the process of radiation inactivation of cells. VIII. Microdosimetry in the analysis of the reproductive death of eukaryotic cells].
    Barsukov VS · Tsitologiia · 1978 · Background
    PubMed: PMID 929699 · NCT02556593 · Carcinoma, Non-Small-Cell Lung

1975 (1 paper)

  1. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
    Pocock SJ, Simon R · Biometrics · 1975 · Background
    PubMed: PMID 1100130 · NCT01652469 (EMPHASIS) · Carcinoma, Non-Small-Cell Lung

1971 (1 paper)

  1. Tumor angiogenesis: therapeutic implications.
    Folkman J · N Engl J Med · 1971 · Background
    PubMed: PMID 4938153 · NCT00442507 (OSI3650) · Esophageal Neoplasms

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Wed, 20 May 2026 23:38:57 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).